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Normal epithelial cells are attached with one another or to the extracellular 
environment by cell-cell or cell-extracellular Matrix (ECM) interactions, 
respectively. By accumulated genetic alterations or other factors, the epithelial 
cells can become tumorigenic, with forming heterogeneous tumor masses.  
Among the tumor cell mass, certain metastatic cells lost their cell polarity and 
cell-cell adhesions, being converted to mesenchymal-like cells. This epithelial-
mesenchymal transition (EMT) is critically involved in the cancer metastasis. 
This EMT process also causes resistance of cancer cells to anti-cancer reagents, 
leading to an attenuation of drug efficiency and enhances migration and invasion 
for metastatic potential of cancer cells. In this study, I investigated how EMT 
causes gefitinib resistance of NSCLC by virtues of TM4SF5 (transmembrane 4 
ii 
L6 family member 5)-mediated EMT induction in NSCLC cells, and how EMT-
rendered mesenchymal properties of cancer cells could regulate invasion of 
TM4SF5-positive and E-cadherin negative to be mesenchymal cells-like, through 
3D collagen I gel systems. One of the most important pathways in NSCLC is the 
epidermal growth factor receptor (EGFR) pathway during tumor progression.  In 
many cases, NSCLC patients can be initially treated with the EGFR-TKI 
(Tyrosine Kinase Inhibitor), gefitinib.  However, continued gefitinib therapy 
does not benefit the survival of patients due to acquired resistance through 
additional EGFR mutations, c-MET amplification, or EMT.  It is of further 
interest to determine whether mesenchymal-like, but not epithelial-like, cancer 
cells can become resistant to gefitinib by bypassing EGFR signaling and 
acquiring alternative routes of proliferative and survival signaling.  Here I 
examined whether gefitinib resistance of cancer cells can be caused by TM4SF5, 
which has been shown to induce EMT via cytosolic p27Kip1 stabilization. 
Gefitinib resistant cells exhibited higher and/or sustained TM4SF5 expression, 
cytosolic p27Kip1 stabilization, and mesenchymal phenotypes, compared with 
gefitinib-sensitive cells. Conversion of gefitinib-sensitive to -resistant cells by 
introduction of the T790M EGFR mutation caused enhanced and sustained 
expression of TM4SF5, phosphorylation of p27Kip1 Ser10 (responsible for 
cytosolic location), loss of E-cadherin from cell-cell contacts, and gefitinib-
resistant EGFR and survival signaling activities. Additionally, TM4SF5 
iii 
overexpression lessened the sensitivity of NSCLC cells to gefitinib. Suppression 
of TM4SF5 or p27Kip1 in gefitinib-resistant cells via the T790M EGFR mutation 
or TM4SF5 expression rendered them gefitinib-sensitive, displaying more 
epithelial-like and less mesenchymal-like characteristics. These results indicate 
that TM4SF5-mediated EMT may have an important function in the gefitinib 
resistance of cancer cells. I have then investigated whether TM4SF5 induced 
EMT for enhanced cell migration and invasion to investigate how mesenchymal 
cell properties following EMT process may regulates the invasive properties such 
as invadopodia formation and ECM degradation in 3D collagen I-surrounded 
condition. The two dimensional (2D) cell culture systems can stratify neither the 
environments around in vivo cancer cells nor evaluation of efficacy of anti-cancer 
drug candidates with regards to cancer cell invasion and metastasis. For this 
reasons, I have used three dimensional (3D) cell culture systems using type 1 
collagen matrices to study invasive behaviors and mechanisms of tumor cells. In 
this 3D cell culture system, revealing the TM4SF5-positive cell behaviors 
involved a technical problem of cell precipitation toward the bottom of the 
collagen I gels, leading to no-real 3D environment. Therefore, alternatively using 
highly-invasive and TM4SF5-positive MDA-MB-231 breast cancer cells, their 
invasive properties in 3D collagen I gels with normal serum-containing media 
were monitored for the underlying mechanisms. Although an in vitro 3D 
environment cannot completely mimic the in vivo tumor site, embedding tumor 
iv 
cells in a 3D extracellular matrix (ECM) allows for our study of cancer cell 
behaviors and the screening of anti-metastatic reagents with a more in vivo-like 
context. I explored the behaviors of MDA-MB-231 breast cancer cells embedded 
in 3D collagen I. Diverse tumor environmental conditions (including cell density, 
extracellular acidity, or hypoxia as mimics for a continuous tumor growth) 
reduced JNKs, enhanced TGFβ1/Smad signaling activity, induced Snail1, and 
reduced cortactin expression. The reduced JNKs activity blocked efficient 
formation of invadopodia labeled with actin, cortactin, or MT1-MMP. JNKs 
inactivation activated Smad2 and Smad4, which were required for 
snail1expression. Snail1 then repressed cortactin expression, causing reduced 
invadopodia formation and prominent localization of MT1-MMP at perinuclear 
regions. MDA-MB-231 cells thus exhibited less efficient invasion in 3D collagen 
I upon JNKs inhibition. These observations support a signaling network among 
JNKs, Smads, Snail1, and cortactin to regulate the invasion of MDA-MB-231 
cells embedded in 3D collagen I, which may be targeted during screening of anti-
invasion reagents. Altogether, this study reveals that mesenchymal properties 
acquired by EMT process, which can be induced by membrane proteins such as 
TM4SF5 can cause drug resistance and enhanced metastatic potentials of cancer 
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1. Cell-Cell adhesion and Cell-Matrix interactions  
Epithelial monolayer on the basement membranes is maintained by adhesions 
between integrins on cell surface and extracellular matrix proteins, and by cell-cell 
adhesions between adjacent cells [1].  Cell-cell adhesion is achieved through 
intercellular junctions composed of the tight junction, adherens junctions, 
desmosome, and cell-matrix junctions (focal adhesion and hemidesmosome) 
between two neighboring cells [2].  Specialized cell junctions occur at adhesion 
molecules complexes of cell-cell and cell-matrix contacts in all tissues (Fig.Ⅰ-1). 
Specially, adherens junctions and tight junctions play a central role in regulating 
the activity of the entire junctional complex [3].  The tight junctions that lie apical 
to adherens junctions regulate the paracellular pathway for the movement of ions 
and solutes between epithelial cells and seal neighboring cells together so that they 
function as barriers to the diffusion of some membrane proteins and lipids between 
apical and basolateral domains of the plasma membrane [4]. Tight junctions are 
mainly composed of occludin and claudin, and the cytoplasmic scaffolding proteins 
ZO-1,-2, and -3 [5]. Adherens junctions mechanically attach cells and their 
cytoskeletons to their neighbors or to the extracellular matrix. Adherens junctions 
composed of the transmembrane protein E-cadherin and intracellular components, 
such as p120-catenin, β-catenin, and α-catenin [4]. The desmosome is a specialized 
adhesive junction that interacts with the cytoskeleton and participates in crosstalk 
２ 
with gap and adherens junctions. Desmosomes appear as thickened patches in the 
cell membrane region between two cells. Desmosomes contain specialized proteins 
such as desmosomal cadherins called desmocollins and desmogleins and are linked 
to intermediate filaments (IFs) through desmoplakin [2] .   
 
Fig. Ⅰ-1. Five different types of junctions [2].  
Cell–matrix adhesions are regulated by hemidesmosomes or focal adhesions that 
are linked to actin filaments by integrins and adaptor proteins such as talin, filamin, 
and vinculin [2].  The cell-matrix interactions play a significant role in in vitro 
models. One example of such significance is the evidence showing alterations in 
the spectrum of molecules involved in cell-ECM interactions in transformed 
malignant cells [6]. Transformed cells are generally characterized by decreased 
３ 
expression of ECM proteins, ECM receptors, and cytoplasmic components of 
adhesion plaques [6]. The downregulation of these molecules is important for 
transformation in a variety of cell types because restoration of their levels reverts 
features of the tumorigenic phenotype such as abnormal cell morphology, 
anchorage-independent growth, and the ability to form tumors in transplantation 
models [6]. These cell-cell adhesion and cell-ECM interactions determine the 
polarity of cells and participate in the maintenance of tissues. The disrupted cell-
cell or cell-ECM adhesion significantly contributes to uncontrolled cell 
proliferation and progressive distortion of normal tissue architecture.  
2. Cell adhesion and EMT in cancer 
Like normal epithelial cells, benign tumor cells in situ maintain cell polarity which 
is supported by cell-cell adhesions and cell-ECM interactions.  However, during 
cancer progression, some carcinoma cells lose the cell polarity and invade through 
their basement membrane and then into connective tissue. This phenomenon is 
referred to as epithelial-mesenchymal transition (EMT) and thought to be a crucial 
event of cancer progression [7-9]. The EMT in cancer is a process by which 
epithelial cells lose their cell polarity and cell-cell adhesion, and gain migratory 
and invasive properties to become mesenchymal cells [10]. During EMT process, 
upstream signals through growth factors of the tumor stroma lead to the activation 
of transcriptional repressors, including ZEB1, Twist, and Snail1 and 2, which 
４ 
directly and indirectly inhibit E-cadherin transcription [11, 12]. E-cadherin which 
is a calcium-dependent cell adhesion molecule is expressed exclusively in 
epithelial cells and its expression is commonly suppressed in tumors of epithelial 
origins. The cytoplasmic domain of E-cadherin interacts with β-catenins to 
establish an intracellular linkage with the actin filaments [13, 14]. This results in 
the disturbance of apico-basal polarity and cell anchoring to the basement 
membrane, which, in turn, allows the cells to acquire a mobile mesenchymal 
phenotype [15].  Loss of cell adhesion and polarity by EMT allows tumor cells to 
detach from primary tissue and to escape from the primary mass.  This event is 
accompanied with morphological changes of cells and transformed cells gain a 
more motile and invasive phenotype. As consequence, non-invasive cells could 
convert to the malignant tumor cells and break down the ECM and eventually 
invade and metastasize to distal organs [11, 15]. Thus, EMT-dependent invasion 
and metastasis programs are strongly responsive to microenvironmental changes 
and adaptive in their signaling program and associated invasion dynamics. 
3. Tumor microenvironment  
Solid tumors contain heterogeneous cell types that comprise cancer cells and 
stromal cells (i.e., fibroblasts and inflammatory cells), and multiple different 
components that are embedded in an extracellular matrix [16]. The tumor 
microenvironment is the cellular environment in which the tumor exists, including 
５ 
surrounding blood vessels, immune cells, fibroblasts, other cells, signaling 
molecules, and the extracellular matrix such as collagen [17, 18]. The tumor and its 
microenvironment affect the fate of one another. Tumor mass can control the 
microenvironment by releasing extracellular signals, such as in tumor angiogenesis 
while the microenvironment helps drive the process of tumor progression such as 
in hypoxia and acidity [19]. The tumor microenvironment is now recognized as an 
important factor of tumor progression and responses to cancer treatment. Recent 
reports demonstrate significant gene expression and epigenetic alterations in cells 
composing the microenvironment during disease progression, which can be 
explored as biomarkers and targets for therapy. As a result, there is increasing 
interest in developing novel therapies targeting the tumor microenvironment, 
particularly as it relates to invasive and metastatic progression [20].  
4. Three dimensional cell culture in cancer 
Tissues and organs in vivo are made three dimensional (3D) constructs of organized 
assembly of different cell types that contribute to the architecture for functional 
differentiation. However, cells grown in vitro on flat 2D tissue culture substrates 
can differ considerably in their morphology, cell-cell and cell-ECM interactions, 
and differentiation form those growing in more physiological 3D environments 
[21]. 3D in vitro cell culture models have an invaluable role in understanding the 
behavior of tumor cells in a well-defined microenvironment [21, 22].  3D cell 
６ 
culture aims at recapitulating normal and pathological tissue architectures, hence 
providing physiologically relevant models to study normal development and 
disease [23]. In 3D culture systems, cells attach and proliferate to one another and 
form natural cell-cell and cell-ECM interactions. Additionally, both the 
composition and stiffness of the ECM have major effects on cell signaling and 
behavior [24-26]. The cell-ECM adhesions synthesize and secrete the natural 
products to which cells are attached in 3D. It is flexible and pliable like in vivo 
tissues. It is made of complex proteins in their native configuration and so provides 
important biological instructions to the cells [21]. The advantages of 3D cell 
culture manifest when mimicking pathological conditions such as cancer and 
specific tissues. In a 3D matrix environment, embedding single tumor cells form  
clustered, and rounded morphology, respectively, and result in individual cell 
migration and invasion, collective cell invasion or mixtures of invasive and 
necrotic cells as they do in vivo like environment [21, 27]. Additionally, 3D cell 
cultures and tissue models should promote advances in tissue engineering and 
could also facilitate the development and screening of new therapeutics [21, 28]. 
For example, cancer cells grown in 2D can easily be killed by low doses of 
chemotherapeutic drugs or low doses of radiation. If those same cells are treated in 
3D matrix environment, they are resistant to the same doses of chemotherapeutic 
drugs or radiation, just like cancer as their found in vivo [29, 30]. For this reason, 
3D cell culture could be more valid methods for testing and discovering new drugs 
７ 
to treat cancer. Besides, providing 3D model systems for testing ideas and potential 
therapeutic interventions, they may also permit high-throughput drug screening on 
human tissues in vitro [21, 29, 30]. 
5. Objective 
Epithelial-Mesenchymal Transition occurs via alteration in cell-cell contacts and 
cellular polarity, and is critical for cancer metastasis. EMT is supportive for 
different biological phenotypes, such as abnormal proliferation, enhanced 
migration, drug resistance, and self-renewal capacities. In this study, I have studied 
on EMT-mediated drug resistance as well as invasion of mesenchymal-like cells 
through 3D collagen gels. In the chapter 1, I focused on the roles of TM4SF5 
(transmembrane 4 L6 family member 5) -mediated EMT in the gefitinib resistance 
of non-small cell lung cancer cells (NSCLC). I have hypothesized that TM4SF5 
expression mediates EMT and leads to acquirement of gefitinib resistance in 
NSCLC. Further in the chapter 2, I have investigated how mesenchymal cell 
properties following EMT process may regulates the invasive properties such as 
invadopodia formation and ECM degradation in 3D collagen I-surrounded 
condition. However, unexpectedly 3D culture system using TM4SF5 stably 
overexpressing cells shows the technical problem of cell precipitation toward the 
bottom of the collagen I gels, which could not mimic real 3D environment. 
Therefore, alternatively using highly-invasive MDA-MB-231 breast cancer cells  
８ 
which express high level of TM4SF5 in 3D collagen I gels were monitored for the 
underlying signaling mechanisms of invasive properties and for an establishment of 















Ⅱ. Chapter 1 
 
 










Based on pathological classification, lung cancer has been categorized into two, 
non-small cell lung cancer (NSCLC; 80% incidence) and small cell lung cancer 
(SCLC; 20% incidence [31].  One of the most important pathways in non-small 
cell lung cancer (NSCLC) is the epidermal growth factor receptor (EGFR) pathway.  
This pathway affects several crucial processes in tumor development and 
progression, including tumor cell proliferation, apoptosis regulation, angiogenesis, 
and metastatic invasion [32]. EGFR is a member of the receptor tyrosine kinase 
(TK) family that includes ERBB2, ERBB3, and ERBB4 [33]. The activation of 
receptor TKs leads to the autophosphorylation of the intracellular domain of EGFR, 
resulting in the activation of the Ras/mitogen-activated protein kinase (MAPK) 
pathway, phosphatidylinositol 3-kinases (PI3K)/Akt pathway, as well as signal 
transducers and activators of transcription signaling pathways [32].  For unknown 
reasons, EGFR kinase domain mutations seem to be restricted to a subset of 
NSCLC, although very rare mutations have also been reported in SCLC, 
cholangiocarcinoma, ovarian, colorectal, head and neck, oesophageal and 
pancreatic cancers [32].  Most NSCLC patients with activating EGFR mutations 
such as exon 19 deletion and the exon 21 L858R substitution were significantly 
sensitive to EGFR-TKIs [34].  Early NSCLC clinical trials can be initially treated 
with tyrosine kinase inhibitors (TKIs), such as epidermal growth factor receptor 
１１ 
(EGFR) inhibitor gefitinib [35, 36]. Treatment with continued EGFR-targeted 
therapy results in tumor responses, which are blunted by the selection or evolution 
of clones with resistant EGFR (T790M or S492R) or activation, upregulation or 
amplification of a bypass pathway such as MET, HER2 or KRAS, or histologic 
transformation, EMT [37] (Fig.1). 
 
Fig. Ⅱ-1. Mechanism of acquired resistance to gefitinib in non-small cell lung 
cancer (NSCLC) 
The T790M mutation occurs in approximately 50% of lung cancer patients with 
mutant EGFR, causes steric hindrance to TKI binding and enhances EGFR affinity 
for ATP with competitively decreased binding to gefitinib, an ATP-competitive 
kinase inhibitor [38, 39]. Except for T790M mutation, resistance to EGFR-targeted 
１２ 
therapies may occur through numerous pathways are clinically validated to trigger 
resistance to EGFR-TKIs and monoclonal antibodies, including amplification of 
KRAS, MET or HER2 (Fig. Ⅱ-1). The EMT was reported as an EGFR resistance 
mechanism in lung adenocarcinoma cell lines [40] and in patients treated with 
EGFR TKIs independent of a T790M mutation [41]. Among NSCLC, 
representatively gefitinib-sensitive (with an IC50 less than 0.025 μM) HCC827 cells 
have a deletion mutation in EGFR (from E746 to A750 in exon 19), whereas 
gefitinib-resistant (with an IC50 higher than 10 μM) NCI-H1975 cells have 
mutations in EGFR of T790M (within exon 20) and L858R (within exon 21) [42, 
43].  However, acquired resistance to gefitinib in NSCLC can also be attributed to 
amplification of c-MET, a gene that encodes a receptor tyrosine kinase for 
hepatocyte growth factor [44].  A subpopulation from gefitinib-sensitive HCC827 
cells (derived from the selection of resistant cells by culturing the cells to 
increasing gefitinib concentrations) demonstrates TKI resistance that maintains 
ErbB3/PI3K/Akt pathway activation and c-MET amplification, and inhibition of c-
MET restored the sensitivity to gefitinib [45].  A gefitinib-resistant subpopulation 
of gefitinib-sensitive A549 cells shows activated PI3K activity and IGF1R pathway 
and inhibition of IGFIR restored the sensitivity to gefitinib [46].  Thus, bypassing 
EGFR signaling for cell growth and proliferation appears to be another mechanism 
for gefitinib resistance.  Additionally, acquired TKI resistance of NSCLC appears 
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to correlate with epithelial–mesenchymal transition (EMT) that affects cell–cell 
contacts [40].  TGFβ1-mediated EMT causes resistance to gefitinib in addition to 
loss of E-cadherin and cytokeratin expression [47].  Thus, mesenchymal-like, but 
not epithelial-like, NSCLC cells may likely be resistant to TKI inhibition such that 
mesenchymal-like cells bypass EGFR signaling and acquire alternative routes of 
proliferative and survival signaling.  For this reasons, membrane receptors may be 
cooperative to specify the alternative signaling pathway(s) or organized to allow 
synergistic or antagonistic relationships between them during communications of 
cancer cells with diverse extracellular cues.  EMT enhances cell proliferation, 
migration, and invasion [48].  In addition to the TGFβ receptor and c-MET 
pathways, tetraspan TM4SF5 also induces EMT with persistent proliferation even 
under confluent conditions [49], and accelerates S-phase entry [50].  TM4SF5 
expression decreases expressions of E-cadherin and ZO-1, and increases expression 
of smooth muscle actin (α-SMA) leading to a loss of cell–cell contacts, depending 
on cytosolic p27Kip1-mediated RhoA inactivation and morphological changes; the 
TM4SF5-mediated EMT is blocked by a suppression of TM4SF5 or p27Kip1 [49].  
Even hepatocyte growth factor (HGF)-mediated EMT of endogenously TM4SF5-
expressing hepatocytes was also blocked by TM4SF5 suppression [49].  The 
tetraspan TM4SF5 homologous to the lung cancer antigen L6 forms the 
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transmembrane 4 L six family with L6, IL-TIMP, and L6D [51].  This family 
shares four-membrane spanning membrane topology with genuine TM4SF 
(transmembrane 4 superfamily) or tetraspanins [52]. TM4SFs are known to regulate 
the integrity of a membrane receptor network, known as a ‘tetraspanin-web’ or 
‘tetraspanin-enriched microdomain (TERM)’ where they collaboratively perform 
their biological function [53].  TM4SF5 collaborates with integrins or growth 
factor receptors for cellular function [54, 55].  Thus, we rationalized that 
gefitinib-resistant cells may adapt an alternative signaling pathway to bypass 
EGFR-dependent proliferation and survival signaling pathways via integrative 
roles by other membrane receptors such as tetraspanins.  In this study, we 
explored whether TM4SF5 was involved in gefitinib resistance of cancer cells, 
because TM4SF5 has been shown to induce EMT and collaborate with other 
receptors on the cell membrane surface [54, 55].  We examined the expression and 
activity levels of signaling molecules in gefitinib-sensitive HCC827 and -resistant 
NCI-H1975 [42, 43] cells to determine whether TM4SF5-mediated signaling and 
cellular function correlate with resistance to gefitinib.  We found that TM4SF5-
mediated effects, including cytosolic p27Kip1 stabilization and EMT, appeared to be 
involved in gefitinib resistance of NSCLC cells 
 
１５ 
2. Materials and Methods 
1. Cells  
HCC827 (with EGFR mutation of deletion from E746 to A750), NCI-H1975 (with 
EGFR mutation of L858R and T790M), NCI-H358 (with K-Ras mutation of G12C) 
lung carcinoma and MKN45 (with c-MET amplification) gastric adenocarcinoma 
cells (ATCC, Manassas, Virginia) were maintained in RPMI-1640 with 10% FBS, 
10 U/ml penicillin, and 10 μg/ml streptomycin at 37 °C and 5% CO2. HCC827 
cells stably-expressing mock or T790M EGFR or FLAG-TM4SF5 were established 
via transfection and G418 (500 μg/ml, A.G. Scientifics) selection and maintained in 
RPMI-1640 containing 10% FBS and 250 μg/ml G418. 
2. Standard Western blots 
Cells were transiently transfected with shRNA against control sequence or 
TM4SF5 for 24 h, or infected with adenovirus encoding for siRNA against control 
or p27Kip1 sequence [49] overnight, before treatment with DMSO or gefitinib (LC 
Laboratories) for 24 h at different concentrations. Cells were then harvested for 
whole cell lysates with RIPA buffer (50 mM HEPES, pH 7.5, 0.1% SDS, 1% NP-
40, 0.5% sodium deoxycholate, 150 mM NaCl, 50 mM NaF, 1 mM Na2VO4, 1 mM 
nitrophenylphosphate, and protease inhibitors). The lysates were normalized and 
processed for standard Western blots using antibody against E-cadherin (#610182, 
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BD Bioscience; sc-8426, Santa Cruz Biotech.), active EGFR (#610025), p27Kip1 
(#610241, BD Transduct. Lab.), pS10p27Kip1 (#AP3191a, ABGENT), β-catenin 
(sc-7963, Santa Cruz Biotech.), pY1173EGFR (#4407), phospho-Y992EGFR 
(#2235), phospho-Y845EGFR (#2231), phospho-Y1045EGFR (#2237), phospho-
Y1068EGFR (#2234), Erk1/2 (#9102, Cell Signaling), phospho-Erk1/2 
(#9101s,Cell Signaling), FLAG (#2368), phospho-S473Akt (#9272, Cell 
Signaling), Akt (sc-7985R, Santa Cruz Biotech.), α-smooth muscle actin (SMA, 
#A2547, Sigma), vimentin (#V5255, Sigma), α-tubulin (#T5168, Sigma), EGFR 
(sc-03, Santa Cruz Biotech.), or TM4SF5 [49].  
3. Cell imaging  
Cells in normal culture media were imaged using a camera quipped CX41 
microscopy (Olympus).  
4. MTT assay  
Cells (3-5 × 103 cells/well) were seeded in 96 well plates and 24 h later DMSO or 
gefitinib was treated at different concentrations (0 to 10 μM) for additional 72 h.  
After the reaction, cells were incubated with 20 μl MTT 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (Sigma) solution for 4 h at 37℃ and added150 μl 
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MTT solvent. Cover with tinfoil and agitate cells on orbital shaker for 5 min and 
read absorbance at 540nm. 
5. Co-Immunoprecipitation 
Whole cell lysates from stably FLAG-mock or FLAG-TM4SF5 expressing 
HCC827 cells under a subconfluent normal culture condition were incubated with 
anti-FLAG M2 sepharose beads (Sigma, 1 mg protein/40 μl of 50% 
slurry/condition) overnight at 4°C, washed twice with lysis buffer, and then twice 
with cold PBS. Immunoprecipitates were boiled within 2× SDS-PAGE sample 
buffer, and immunoblotted with anti-FLAG M2 (#2368, Sigma) or -EGFR (sc-03, 
Santa Cruz Biotech.) antibody. 
6. Indirect immunofluorescence  
Cells were seeded on precoated cover slips coated with fibronectin (10 mg/mL; BD 
Biosciences). The cells were incubated with normal conditions (10% FBS in RPMI 
1670) for overnight and then treated with DMSO or 0.01 μM gefitinib for 
additional 18 h and fixed in 4% paraformaldehyde in PBS for 5 minutes. After 
being thoroughly washed with PBS, the cells were blocked with 3% BSA in PBS, 
and stained with anti-E-cadherin (#610182, BD Biosource) and vimentin(#V5255, 
Sigma) or anti-p27Kip1 (#610241, BD Transduction, Lab) antibodies.  DNA in 
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nucleus was stained by DAPI (Molecular Probes). Epifluorescence Microscope 
images were acquired on a microscope (BX51TR, Olympus) using 406/0.75 or 
1006/1.3 (oil) NA U plan semi Apochromat objective lens (Olympus). The filters 
for GFP or Red fluorescent protein (RFP) were XF105-2 or XF115-2, respectively. 
A JVC KY-F75U CCD digital camera with IEEE 1394 interface was used. The 
TOMORO image analyzer software (Techsan Community Co., Korea) was used 
for image analysis. 
7. DNA sequencing  
DNA was extracted from cell pellets using the QIAamp DNA Mini kit (Qiagen, 









1. Gefitinib-resistant NCI-H1975 cells efficiently grow in a scattered 
pattern despite decreased EGFR signaling activity 
While trying to understand the mechanisms underlying gefitinib resistance of 
NSCLC cells, we hypothesized that resistance might be caused by alternative 
signaling pathways emanating from membrane receptors that closely collaborate 
with EGFR.  To test this hypothesis, we first compared the characteristics of 
gefitinib-sensitive HCC827 and -resistant NCI-H1975 cells [42].  To first confirm 
their susceptibility to gefitinib, we performed MTT assay using the cell lines 
treated with vehicle or gefitinib at various concentrations (0 to 10 μM).  As we 
expected, HCC827 cells were sensitive to gefitinib with an IC50 of approximately 
0.02 μM, whereas NCI-H1975 cells were resistant with an IC50≥10 μM (Fig. Ⅱ-
2A).  Immunoblotting for EGFR and survival signaling molecules from 
subconfluent cells cultured under normal culture conditions showed that HCC827 
cells exhibited higher phosphorylation and activity of EGFR than NCI-H1975 cells, 
whereas phosphorylation of Akt and Erk1/2 was slightly higher in the NCI-H1975 
cells (Fig. Ⅱ-2B, middle).  NCI-H1975 cells were more efficiently proliferative 
under normal culture conditions, compared with HCC827 cells (Fig. Ⅱ-2C).  
This pro-proliferative phenotype of NCI-H1975 cells indicates that alternative 
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EGFR-bypassing signaling pathway(s) may still be prominent.  Additionally, 
NCI-H1975 cells grew in a scattered pattern whereas HCC827 cells grew in 
colonies (Fig. Ⅱ-2D).  We also checked the expression level of TM4SF5 because 
of its pro-proliferative function [49] and role in EMT [57].  NCI-H1975 cells with 
a higher TM4SF5 expression showed a less E-cadherin (an epithelial marker) 
expression but more α-SMA and vimentin (mesenchymal markers) expressions, 
compared with HCC827 cells expressing a lower TM4SF5 level (Fig. Ⅱ-2B, 
bottom); thus, highly expressed TM4SF5 might presumably cause a scattered-
growth pattern (Fig. Ⅱ-2D). Being consistent, HCC827 cells growing in a 
cobblestone pattern well-established cell–cell adhesions with E-cadherin at the 
cell–cell contact sites but showed a less vimentin expression, whereas NCI-H1975 
cells growing in a scattered pattern showed less significant cell–cell adhesions with 
a lower E-cadherin expression and a more vimentin expression (Fig. Ⅱ-2E).  
Interestingly, both HCC827 and NCI-H1975 cell lines were not homogeneous with 
regards to E-cadherin and vimentin expressions; cell–cell contacts between 
HCC827 cells thus showed more E-cadherin in certain contacts but less in other 
contacts (Fig. Ⅱ-2E up and left), and NCI-H1975 cells showed more vimentin in 
certain cells but less in other cells (Fig. Ⅱ-2E, bottom and right).  Taken together, 
these results suggest that NCI-H1975 cells have certain growth and survival 
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signaling activities presumably via TM4SF5 that are sufficient to alternatively 
bypass the EGFR signaling pathway, where a higher relative level of TM4SF5 to 
EGFR expression in NCI-H1975 cells was correlative with a less dependence on 
EGF signaling, compared with HCC827 cells, although cells might have 
















Fig. Ⅱ-2. Gefitinib-resistant NCI-H1975 cells efficiently grow in a 
scattered pattern despite decreased EGFR signaling activity.  (A) 
Gefitinib-sensitive HCC827 and -resistant NCI-H1975 cells were analyzed for 
survival in the presence of treatment with gefitinib at different concentrations (0 to 
10 μM) via MTT assay. Each value was averaged from hexaplicate in one 
experiment of 3 independent MTT assay (i.e., hexaplicate×3 times).  (B) The 
subconfluent cells were harvested and processed for standard Western blots for the 
indicated molecules.  (C) Proliferations of the cells in the normal culture media 
were examined by determination of cell numbers at different times after cell 
seeding at the same number.  (D) Phase-contrast images were saved at a 
subconfluent condition within the normal culture media.  (E) Cells were seeded 
onto normal culture media-precoated cover glasses for 24 h and then 
immunostained for E-cadherin or vimentin, as explained in the Materials and 







2. Survival of gefitinib resistant cells in the presence of gefitinib 
correlated with sustained TM4SF5 expression 
Further, the cells resistant to gefitinib due to an active mutation (G12C) in K-Ras 
(NCI-H358 cells) or amplification of c-MET (MKN45 cells) showed values of IC50 
against gefitinib higher than 10 μM (data not shown) and also showed higher and 
sustained expressions of TM4SF5 in the presence of gefitinib treatment, compared 
to gefitinib-sensitive HCC827 cells (Fig. Ⅱ-3A and B).  Interestingly, EGFR 
inhibition in gefitinib-sensitive HCC827 cells caused a reduced TM4SF5 
expression (Fig. Ⅲ-A and B), which may be explained by the observations that 
TM4SF5 induction involves a cross-talk between TGFβ1 and EGFR signaling 
pathways and inhibition of EGFR activity abolishes the TM4SF5 expression [58].  
This correlation between gefitinib resistance and sustained TM4SF5 expression 
may indicate a close functional relationship between EGFR and TM4SF5.  Such 
an indication may also be supported by a concept that TM4SF5 as a tetraspanin or 
TM4SFs can function in regulation of membrane receptor integrity on cell surface 
[59].  Thus, we next examined whether a physical linkage between EGFR and 
TM4SF5 exists.  From HCC827 cells stably-transfected with FLAG-mock or 
FLAG-TM4SF5 plasmid, EGFR was co-immunoprecipitated with FLAG-TM4SF5 
and vice versa (Fig. Ⅱ-3B).  These observations indicate that TM4SF5 may play 
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roles in the signaling for sufficient growth of the gefitinib-resistant cells, 































Fig. Ⅱ-3. Survival of gefitinib resistant cells in the presence of gefitinib 
correlated with sustained TM4SF5 expression. (A and B) Sub-confluent 
gefitinib-sensitive HCC827 and –resistant NCI-H1975, MKN45, and H358 cells 
were grown with or without gefitinib at different concentrations for 24 h before 
preparation of whole cell lysates. (C) Whole cell lysates from sub-confluent 
FLAG-mock and FLAG-TM4SF5-stably expressing cells were immunoprecipitated 
with anti-FLAG M2 or -EGFR antibody-conjugated with sepharose before 















3. Sustained EGFR, Erk, and Akt signaling activities in gefitinib-
resistant cells after gefitinib treatment correlated with TM4SF5-
mediated effects, including cytosolic p27Kip1 stabilization 
When cells were treated with gefitinib at different concentrations from 0 to 1.0 μM, 
phosphorylation of EGFR, Akt, and Erk1/2 in gefitinib-resistant NCI-H1975 cells 
was sustained. However their basally-robust phosphorylation in gefitinib-sensitive 
HCC827 cells was dramatically reduced (Fig. Ⅱ-4A), as we have shown 
previously[60].  We thus tried to test whether such a differential response to 
gefitinib between HCC827 and NCI-H1975 cells might also correlated with higher 
and sustained TM4SF5 expression.  Sustained TM4SF5-expression correlated 
with a different pattern of signaling activities between both cell lines treated with 
gefitinib: TM4SF5 levels in NCI-H1975 cells were highly sustained even with 
gefitinib treatment whereas TM4SF5 levels in HCC827 cells were reduced (Fig. 
Ⅱ-4A, bottom).  An enhanced and sustained TM4SF5 expression results in 
stabilization of p27Kip1 in the cytosol during TM4SF5-mediated EMT, multilayer 
growth [49], and acceleration of G1- to S-phase entry [50].  Therefore, cytosolic 
p27Kip1 appears to play pro-tumorigenic roles in cell proliferation and migration.  
We thus examined the localization and expression of p27Kip1 in HCC827 and NCI-
H1975 cells in the absence or presence of gefitinib.  Without gefitinib treatment, 
HCC827 cells showed p27Kip1 expression mostly in the nucleus whereas NCI-
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H1975 cells clearly demonstrated cytosolic p27Kip1 (Fig. Ⅱ-4B, top).  With 
gefitinib treatment, HCC827 cells exhibited more enhanced p27Kip1 in the nucleus, 
suggestive of the gefitinib-mediated cell growth arrest and death.  However, NCI-
H1975 cells still showed cytosolic p27Kip1 stabilization (Fig. Ⅱ-4B, bottom), 
indicating that TM4SF5 in NCI-H1975 cells might play tumorigenic roles even in 























Fig. Ⅱ-4. Sustained EGFR, Erk, and Akt signaling activities in gefitinib-
resistant cells on gefitinib treatment correlated with TM4SF5-mediated effects 
including cytosolic p27Kip1 stabilization.  Cells were treated with gefitinib at 
different concentrations (0 to 1.0 μM) for 24 h before preparation of whole cell 
lysates for immunoblottings for the indicated molecules (A), or reseeded on cover 
glasses precoated with fibronectin (10 μg/ml) for 2 h with DMSO or 0.01 μM 
gefitinib treatment before staining or indirect immunofluorescence using DAPI 
(blue) or anti-p27Kip1 antibody (green), respectively (B).  Scale bars depict 20 μm. 










4. T790M EGFR mutation-mediated gefitinib resistance correlated with 
sustained TM4SF5 expression and EMT process 
The T790M EGFR mutation renders gefitinib resistance in NSCLC cells [34].  
Therefore, we investigated whether T790M EGFR introduction into HCC827 cells 
(already with EGFR mutation of deletion from E746 to A750) caused cells to 
concomitantly become gefitinib-resistant and display TM4SF5-mediated 
phenotypes. When the MTT assay was performed with HCC827 stable 
transfectants (mock and T790M EGFR clones 1–5 and 2–1) and NCI-H1975 cells 
in the presence of gefitinib treatment at different concentrations for 72 h, HCC827-
T790M clones and NCI-H1975 cells clearly showed resistance to gefitinib, 
although HCC827 mock cells were sensitive (Fig. Ⅱ-5A).  HCC827-T790M 
clones enhanced and sustained the phosphorylation of EGFR and Akt after gefitinib 
treatment (Fig. Ⅱ-5B).  Unlike HCC827 mock cells growing in a pattern of 
cobble stones, HCC827-T790M cells grew in a scattered pattern (Fig. Ⅱ-5C).  
HCC827-T790M cells also increased α-SMA (a mesenchymal marker) and 
decreased E-cadherin (an epithelial marker) expression, indicating an EMT by 
T790M EGFR introduction, which were accompanied with enhanced and sustained 
TM4SF5 expression in the presence of gefitinib treatment (Fig. Ⅱ-5D). T790M 
EGFR transfection-mediated growth pattern in a scattering pattern was correlated 
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with the loss of E-cadherin from cell–cell contacts and more p27Kip1 in the cytosol 
compared with mock-transfectants (Fig. Ⅱ-5E). These observations using 
HCC827-T790M clones may suggest that TM4SF5 is involved in gefitinib 



















Fig. Ⅱ-5. T790M EGFR mutation-mediated gefitinib resistance correlated 
with sustained TM4SF5 expression and EMT process. (A) HCC827 cells stably-
transfected with mock or T790M EGFR plasmids or NCI-H1975 cells were 
processed to MTT assay with DMSO or gefitinib treatment at different 
concentrations (0.001 to 10 μM).  Each value was averaged from hexaplicate in 
one experiment of 3 independent MTT assay (i.e., hexaplicate x 3 times).  (B and 
D) The cells were treated with DMSO or gefitinib at different concentrations for 24 
h before whole cell lysates preparation for standard Western blots for the indicated 
molecules.  (C) Subconfluent cells were imaged using a phase-contrast 
microscope.  (E) HCC827 cells stably transfected with mock or T790M EGFR 
(clones 1–5) were reseeded on cover glasses precoated with fibronectin (10 μg/ml) 
for 2 h before indirect immunofluorescence to co-stain nuclear DNA (blue with 
DAPI) and E-cadherin (green, left) or p27Kip1 (green, right).  Scale bars: 20 μm.  






5. TM4SF5 overexpression rendered gefitinib-sensitive cells to be 
gefitinib-resistant cells with EMT phenotypes  
To test whether enhanced and sustained TM4SF5 expression causes gefitinib-
resistance, we overexpressed TM4SF5 in HCC827 cells and examined whether the 
stable HCC827-TM4SF5 transfectants might become resistant against gefitinib, 
using the MTT assay.  When cells were treated with gefitinib at different (0 to 10 
μM) concentrations, TM4SF5-overexpressing HCC827 clones showed less 
sensitivity to gefitinib than did HCC827 mock cells, although they were less 
resistant than HCC827-T790M2–1 cells (Fig. Ⅱ-6A).  At 0.01 μM gefitinib 
treatment, all TM4SF5-positive clones were significantly (p≤0.05) gefitinib-
resistant differently from gefitinib-sensitive HCC827 cells, whereas at a higher 0.1 
μM, HCC827-TM4SF52–8 clone was insignificantly gefitinib-resistant, similar to 
HCC827 cells (Fig. 5A). This observation indicates that the TM4SF5 expression 
may not be all requirements for the gefitinib resistance.  Additionally, the 
HCC827-TM4SF5 clones not only enhanced and sustained phosphorylation of 
EGFR and Akt but also enhanced TM4SF5 expression and p27Kip1 Ser10 
phosphorylation, which is known to cause its cytosolic localization [49], although 
their levels were slightly differential between clones (Fig. Ⅱ-6B).  Indeed, 
compared with HCC827 cells, HCC827-TM4SF5 cells clearly showed cytosolic 
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localization of p27Kip1 under basal and gefitinib-treated conditions (Fig. Ⅱ-6C). 
HCC827-TM4SF5 cells also grew in a scattered pattern (Fig. Ⅱ-6D), and showed 
increased mesenchymal marker expression (i.e., vimentin and α-SMA) and 
decreased an epithelial marker expression such as E-cadherin (Fig. Ⅱ-6E), again 



























Fig. Ⅱ-6. TM4SF5 overexpression rendered gefitinib-sensitive cells to be 
gefitinib-resistant cells with EMT phenotypes.  (A) HCC827 cells stably-
transfected with mock, T790M EGFR, or TM4SF5 plasmids were analyzed by 
MTT assay for cell survival with DMSO or gefitinib treatment from 0.001 to 10 
μM. Each value was averaged from hexaplicate in one experiment of 3 independent 
MTT assay (i.e., hexaplicate×3 times). (B, C, and E) Subconfluent HCC827-mock 
or -TM4SF5 stable clones were treated with DMSO or 0.01 μM gefitinib for 24 h 
and then harvested for standard Western blots for the indicated molecules (B and E), 
or reseeded on fibronectin (10 μg/ml) -precoated cover glasses for 2 h before DAPI 
staining (of nuclear DNA) and indirect immunofluorescence using anti-p27Kip1 
(green) antibody (C).  Scale bars depict 20 μm. (D) The cells were imaged using a 
phase-contrast microscope or seeded onto the normal culture media-precoated 
cover glasses for 24 h and then immunostained for E-cadherin or vimentin, as 
explained in the Materials and methods section.  Data shown represent 3 





6. Gefitinib resistance was reduced via suppression of TM4SF5 or 
p27Kip1 
TM4SF5 expression stabilizes cytosolic p27Kip1 through enhanced stabilities of its 
mRNA and protein, and is correlated with the EMT process [49].  Therefore, we 
next examined whether suppression ofTM4SF5 or p27Kip1 would revert gefitinib 
resistance of HCC827-T790M2–1 or HCC827-TM4SF5 cells.  TM4SF5 
suppression reduced phosphorylation of Akt (pS473Akt) and reduced mesenchymal-
like characteristics via increased E-cadherin but reduced α-SMA levels (Fig. Ⅱ-
7A).  Although basal p27Kip1 was slightly increased presumably due to 
cytotoxicity, Ser10 phosphorylated p27Kip1 (i.e., cytosolic p27Kip1) decreased on 
TM4SF5 suppression, compared with control shRNA-transfection (Fig. Ⅱ-7A).  
It is thus likely that TM4SF5 suppression might block the TM4SF5-mediated 
effects on cytosolic p27Kip1 stabilization and EMT and consequently gefitinib 
resistance.  Meanwhile, when HCC827-T790M2–1 cells were infected with 
adenovirus expressing small interfering RNA (siRNA) against a control scrambled 
sequence or p27Kip1.  Suppression of p27Kip1 in HCC827-T790M2–1 cells decreased 
phosphorylation of EGFR and Akt and enhanced the expression of E-cadherin and 
β-catenin under both basal and gefitinib-treated conditions, indicating that 
mesenchymal characteristics of HCC827-T790M2–1 cells were changed to epithelial 
characteristics after p27Kip1 suppression (Fig. Ⅱ-7B). Although HCC827-T790M2–1 
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cells were still more gefitinib resistant compared with the HCC827-T790M2–1 cells 
with a suppressed TM4SF5 or p27Kip1 level, the cells showed a certain inhibition of 
EGFR by gefitinib (Fig. Ⅱ-7A and B), presumably because the exogenous T790M 
EGFR expression level of HCC827-T790M2–1 cells might not be dominant over the 
endogenous EGFR level.  Alternatively, it may be likely that HCC827-T790M2–1  
cells did not accompany the primary EGFR mutation such as the L858R mutation, 
so that L858R-T790M-EGFR-mediated affinity to ATP would not be available to 
cause an efficient blocking of ATP-competitive kinase inhibitor, gefitinib [39].  
Being correlated, the p27Kip1-suppressed cells reduced phosphorylation of Akt 
under basal conditions and further decreased activation of Akt after gefitinib 
treatment compared with non-suppressed cells, indicating that p27Kip1 suppression 
enhanced susceptibility to gefitinib treatment (Fig. Ⅱ-7B).  Such a reversion from 
gefitinib-resistant to -sensitive cells via suppression of p27Kip1 also occurred in 
HCC827 cells overexpressing TM4SF5 (HCC827-TM4SF52–3), which decreased 
α-SMA, phosphorylation of EGFR and Akt but increased β-catenin after p27Kip1 














Fig. Ⅱ-7. Gefitinib resistance was reduced via suppression of TM4SF5 or 
p27Kip1. HCC827 cells stably transfected with T790M EGFR (A and B) or with 
TM4SF5 (C) were transiently transfected with shRNA against control sequence or 
TM4SF5 (A) or infected with adenovirus expressing siRNA against control 
sequence or p27Kip1 overnight (B and C) and then treated with DMSO or 0.01 μM 
gefitinib for 24 h. Whole cell lysates were prepared, normalized and processed to 













In the present study, we observed that gefitinib resistance in cancer cells could 
result from expression of TM4SF5, leading to EMT, at least through cytosolic 
p27Kip1 stabilization. So far evidence exists that gefitinib resistance in cancer cells 
is attributed to acquired mutations in EGFR (e.g., T790M) during TKI therapy that 
cause steric hindrance to gefitinib and enhance the affinity of mutated EGFR for 
ATP, thus lowering the affinity for gefitinib [38] to blunt the hypersensitivity of 
activating EGFR mutations [39]. T790M mutation-mediated gefitinib resistance 
accounts for 50% of TKI resistance in NSCLC patients carrying an EGFR 
mutations[39]. The resistance has also been attributed to the contribution of other 
membrane receptors or their downstream effectors. Gefitinib resistance of A549 
cells is caused by PI3K activation and IGF1R pathway [46], which are suggested to 
be alternative pathways for proliferation that bypass the EGFR signaling pathway 
[39]. Additionally, PI3K/Akt activity and c-MET amplification, which accounts for 
20% of TKI-resistant tumors [39], also result in gefitinib resistance of NSCLC [45]. 
However, c-MET is well-known to cause cell scattering and EMT as a receptor for 
hepatocyte growth factor [61]. Furthermore, loss of molecules at cell–cell contacts 
has recently been reported to be a possible determinant of sensitivity of NSCLC 
cells and xenografts against erlotinib, another EGFR kinase inhibitor [40]. 
Interestingly, as shown in the present study, TM4SF5, as a membrane protein that 
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induces EMT [49, 51], causes gefitinib resistance, and gefitinib-resistant cells with 
the T790M EGFR mutation (i.e., NCI-H1975 cells) showed enhanced expression of 
α-SMA and TM4SF5 as well. Stable transfection of T790M EGFR into HCC827 
cells led to gefitinib resistance, enhanced TM4SF5 expression, and was correlated 
with EMT because the stable transfectants demonstrated enhanced expression of 
mesenchymal markers (i.e., vimentin and α-SMA) but reduced epithelial marker 
(i.e., E-cadherin). Stabilization of p27Kip1 in the cytosol has been shown in diverse 
tumor tissues [62], and accounts for inactivation of RhoA GTPase via direct 
interaction, resulting in regulation of actin dynamics and cell migration [63, 64]. 
TM4SF5 expression causes cytosolic p27Kip1 stabilization, and EMT with loss of E-
cadherin expression, while suppression of TM4SF5 or p27Kip1 recovers E-cadherin 
expression at cell–cell contacts [49].  Additionally, suppression of p27Kip1 results 
in a delay of TM4SF5-accelerated G1- to S-phase entry [50]. Interestingly, 
cytosolic p27Kip1 might also be involved in gefitinib resistance of NSCLC that is 
mediated by TM4SF5 or EGFR T790M expression, because suppression of p27Kip1 
in gefitinib-resistant cells rendered these cells to be gefitinib sensitive. Therefore, 
cytosolic p27Kip1 appears to be tumorigenic by being involved in TM4SF5-
mediated EMT, although nuclear p27Kip1 can be anti-tumorigenic as a cyclin-
dependent kinase inhibitor [65].  In addition to being related to EMT, TM4SF5 as 
a tetraspanin traversing the membrane four times may presumably locate to the 
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tetraspanin-enriched microdomain (TERM) of the cell plasma membrane, playing 
roles in organizing the integrity of membrane receptors including integrins and 
growth factor receptors through massive protein–protein interactions [53, 66, 67]. 
Integrin α5 binds to TM4SF5 and is more efficiently retained on the surface of 
hepatocytes that express TM4SF5, compared with the surface of cells lacking 
TM4SF5 [54].  Similarly, CD63 and CD82 are more likely to be found on the 
surface of cells that overexpress L6-Ag [68], which is another member of the 
transmembrane 4 L six family [52]. Thus, it cannot be ruled out that IGF1R, a 
player in TKI resistance [46], may also be susceptible to TM4SF5- or tetraspanin-
mediated organization of receptor networks on the cell surface. TM4SF5-mediated 
regulation of membrane receptor networks on the cell surface may also lead to the 
gefitinib resistance. In the present study, we observed that gefitinib-sensitive cells 
showed a higher basal EGFR activity, compared with gefitinib-resistant cells. 
However, the EGFR activity of gefitinib-sensitive cells was dramatically reduced 
after gefitinib treatment, whereas the EGFR activity of resistant cells was more 
persistent (similar to the basal level) even after gefitinib treatment. Therefore, such 
persistent EGFR activity of resistant cells after gefitinib treatment might result 
from effective retention of EGFR on the cell surface via a physical linkage between 
TM4SF5 and EGFR. Indeed, in the present study, we have observed that gefitinib-
resistant cells showed a co-immunoprecipitation between the both receptors. 
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Therefore, TM4SF5-mediated effects, including EMT and membrane retention of 
EGFR via protein interactions, may be involved in gefitinib resistance of cancer 
cells.  
 In epithelial cells, TM4SF5 is shown to interact with integrins α2 or α5 during 
migration or angiogenesis, respectively [54, 55].  In Cos7 fibroblasts, TM4SF5 
regulates actin remodeling and focal adhesion dynamics through an interaction 
with integrin α2, which is negatively controlled by serum treatment [69]. It is thus 
likely that cross-talks between TM4SF5 and other membrane receptors such as 
integrins or growth factor receptor are involved in the regulation of diverse cellular 
functions, including cell–cell adhesions. It is suggested that different TERM 
constituents may lead to diverse membrane properties such as signaling, 
cytoskeletal connection or curvatures for different cellular functions [70]. In 
addition to TM4SF5 [48, 49], another tetraspanin, CD151 is also shown to induce 
EMT via a signaling through integrin α6β1 and PI3K [71]. Growth factor receptors 
or receptor tyrosine kinases, such as c-MET is also well-connected with EMT [72]. 
Furthermore, attenuation of EGFR signaling activity is obviously correlated with 
mesenchymal cell features [73]. Therefore, depending on roles of tetraspanins 
through massive protein–protein interactions at TERMs, tetraspanins may be 
４９ 
involved in regulation of growth factor receptor activity and concomitantly of cell–
cell adhesions. 
Continuous EGFR-TKI therapy causes drug resistance by acquired EGFR T790M 
mutation [39]. In the current study, we found that introduction of EGFR T790M 
into gefitinib-sensitive NSCLC cells also resulted in gefitinib resistance and 
TM4SF5 overexpression. Furthermore, overexpression of TM4SF5 in gefitinib-
sensitive cancer cells resulted in gefitinib resistance, although it occurred at a 
resistance level less than that of the EGFR T790M mutation, probably indicating 
that more than TM4SF5 might be involved in gefitinib resistance. Such TM4SF5 
overexpression-mediated resistance to gefitinib appeared not to involve the 
secondary acquired EGFR mutation at T790 or other residues, because resistant 
cells via TM4SF5 overexpression did not show any acquired EGFR mutation 
within exons 18, 19, 20, and 21 (Table 1). Therefore, TM4SF5 may transduce an 
alternative signaling pathway that bypass the EGFR signaling pathway, accounting 
for another major portion of gefitinib resistance in lung cancer irrelevant to 
acquired EGFR mutation of T790M. Interestingly, the gefitinib resistant cells 
alternatively due to c-MET amplification (MKN45 cells) or K-Ras activation (NCI-
H358 cells) also showed higher expression levels of TM4SF5, compared to 
gefitinib-sensitive HCC827 cells. It may thus be likely because TM4SF5 can 
possibly be involved both in EMT mediated and in EGFR-bypassing signaling-
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mediated resistance against gefitinib. Being consistent, TM4SF5 overexpression 
accelerates cell cycle progression from G1 phase to S phase [50], suggesting that 
TM4SF5 may efficiently stimulate a cell growth-stimulatory signaling even in the 




















Table 1. TM4SF5-overexpressing HCC827-TM4SF5 clone cells do not 
accompany any mutations in EGFR. The HCC827-TM4SF5 clone cells were 
analyzed for any mutations in EGFR at exon 18, 19, 20, and 21.  Cell pellets 
prepared from trypsinization were used for genomic DNA preparation and EGFR 
sequencing, as described previously [56].  Note that no mutations in EGFR were 













Fig. Ⅱ-8. TM4SF5-mediated EMT induced gefitinib resistance of NSCLC 
cells. 
 In this chapter, we showed that acquired EGFR T790M mutation- and/or 
TM4SF5-mediated EMT induced gefitinib resistance of HCC827 cells which are 
sensitive to gefitinib. TM4SF5-mediated EMT and regulation of activity or 
integrity of membrane receptors including EGFR, IGF1R, and/or c-MET on the 
cell surface, may likely be important for gefitinib resistance of cancer cells. It may 
thus be interesting to examine whether gefitinib-resistant lung cancer patients 
overexpress TM4SF5, compared with gefitinib-sensitive patients, to get idea 
whether anti-TM4SF5 reagent may be a therapeutic reagent against gefitinib-






Ⅲ. Chapter 2 
 
Regulation of migration and invasion of 









During metastasis, migration and invasion of cancer cell are dynamically regulated 
by coordinated signaling pathways that respond to the extracellular matrix (ECM) 
or soluble factors of the tumor microenvironment [74]. Invasion involves 
degradation of the ECM via formation of invasive morphological features 
including invadopodia and podosomes, which sense the ECM around the edges of a 
cell and involve adhesion-dependent signaling activities [75, 76]. Invadopodia are 
invasive protrusions with proteolytic activity including MT1-MMP uniquely found 
in tumor cells [77]. Invadopodia can regulate by cortactin during precursor 
formation (stage 1) which forms a complex involving cortactin, Arp2/3 and N-
WASp binding domains. Cortactin is then tyrosine phosphorylated, which activates 
cofilin’s severing activity to generate free barbed ends and the Arp2/3 complex can 
use these cofilin generated efficient actin polymerization (stage 2). Cortactin is 
then dephosphorylated, which stabilizes the invadopodium precursor for 
maturation (stage 3). Finally, matured invadopodium efficiently degrades ECM 
(stage 4) [78]. The formation of invasive features involves dynamic actin 
remodeling. c-Src-mediated cortactin phosphorylation causes activation of Arp2/3, 
consequently leading to actin branching and polymerization at lamellipodia and 
invadopodia [78, 79].  
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Fig. Ⅲ-1. Cortactin controls the stages of invadopodium assembly and 
maturation [78]. 
Therefore, cell migration, invasion, and the formation of invasive morphological 
features could be targets to prevent cancer metastasis. However, investigating the 
mechanisms behind certain cell behaviors is critical for developing more effective 
targeted-therapies. While informative, studies investigating the effects of 
extracellular cues on cell functions in two dimensional (2D) conditions may not 
relate to the in vivo or in situ behaviors of cancer cells, because cancer lesions are 
exposed to a 3D microenvironment [21, 80]. Cell behaviors, including migration 
and invasion, are often investigated in a 2D environment. Although the 
significance of the tumor microenvironment in promoting tumorigenesis and 
metastasis has been suggested in many in vitro and in vivo studies [81], studies 
evaluating cells in a 2D environment are limited to mimic in vivo tumor lesions, 
whereas embedding cells in a 3D environment allows for the cells to receive and 
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respond to environmental cues like in vivo situation. The tumor microenvironment 
includes ECM proteins, neighboring cells, and soluble factors consisting of growth 
factors, cytokines, and chemokines, which influence cancer cell function and 
behavior, and have been targeted for clinical treatment [82]. Various environmental 
stressors including ECM stiffness, extracellular acidity, and intratumoral hypoxia, 
can affect cancer cells and neighboring stromal fibroblasts and inflammatory cells 
eventually leading to metabolic alterations, the stimulation of mitogenic and 
survival signaling pathways [83] . Studies evaluating cells in a 2D environment are 
limited in their ability to mimic in vivo tumor lesions, whereas embedding cells in a 
3D environment allows for the cells to receive and respond to environmental cues 
like in vivo situation. Although an in vitro 3D environment cannot completely 
mimic the in vivo tumor site, studying the mechanistic behaviors of cancer cells in 
a 3D environment is beneficial for clinical and pharmaceutical purposes. In this 
study, we evaluated whether and how the invasive behaviors of MDA-MB-231 
breast cancer cells embedded in a 3D collagen I gel could be regulated. Exposing 
the MDA-MB-231 cells to various environmental parameters during culture in the 
3D collagen gels decreased JNKs signaling activity (i.e., decreased Ser63 
phosphorylation of c-Jun, pS63c-Jun), activated TGFβ1/Smads signaling, 
enhanced Snail1 expression levels, and reduced cortactin expression levels. 
Inactivation of the JNKs signaling pathway led to the Smad2/Smad4-activation-
mediated expression of Snail1, which in turn suppressed cortactin. As a result, 
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invadopodia formation was less efficient within the 3D collagen I gels, further with 
cortactin and/or membrane type I matrix metalloproteinase (MT1-MMP) 
localization at perinuclear regions, leading to less migration and invasion. 
Therefore, the signaling network consisting of JNKs, Smads, Snail1, and cortactin 
was revealed to modulate migration and invasion of the MDA-MB-231 cells 












2. Material and Methods 
1. Cells, plasmids, and siRNAs 
MDA-MB-231, MDA-MB-436, MDA-MB-468, T47D, and MCF7 breast 
adenocarcinoma cells were obtained from the American Type Culture Collection 
and grown in complete RPMI-1640 (JBI., Daegu, Korea) supplemented with 10% 
FBS (fetal bovine serum, GIBCO, Invitrogen) and antibiotics (GIBCO, Invitrogen). 
Cells were grown in a humidified incubator with 5% CO2 at 37°C.  DNA plasmids; 
pcDNA3-DN-JNK1, pcDNA3-Flag-Snail1 WT, pmCherry-MT1-MMP, or pEGFP-
cortactin WT were transfected before being embedded in 3D collagen type I gel 
(PureCol., Advanced BioMatrix, San Diego, CA).  Some cells were co-transfected 
with fluorescein conjugated SignalSilence® control siRNA and SignalSilence® 
SAPK/JNK siRNA (Cell Signal Technology) or On-Target plus Smartpool siRNA 
duplexes each were designed to target human snail1 (NM_005985 Dharmacon, 
Lafayette, CO).  As a negative control, cells were transfected with nonspecific 
siRNA pool (Dharmacon).  All cDNA vectors or siRNA transfections were done 
with LipofectamineTM 2000 (Invitrogen) according to the manufacturer’s 
instructions. 
2. Polydimethylsiloxane device fabrication  
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A polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning) prepolymer was 
made using a 10:1 (w/w) mixture of PDMS base and curing agent that was cast 
against the master and thermally cured to obtain a negative replica-molded piece.  
After separation from the master, 4-or 8-well chamber was punched out of the 
molded PDMS with an 8 mm biopsy punch.  The PDMS devices and glass 
coverslips were cleaned with residue-free tape and N2 gas air gun, and then treated 
with oxygen plasma for 45 sec to form covalent bonding between them.  To 
restore hydrophobicity to the PDMS after plasma treatment, the devices were kept 
in 60°C dry oven for at least 24 h and sterilized by UV irradiation before uses. 
3. Antibodies and reagents 
Antibodies and reagents were obtained from the following sources; Sigma-Aldrich, 
10x RPMI, α-tubulin; BD Biosciences, anti-cortactin mAb (4F11), -human HIF-1α 
and BD Matrigel™ Basement Membrane Matrix; Cell Signal Technology, anti-snail 
mAb (L70G2), anti-smad2/3, anti-phospho-smad2, anti-phospho-smad3, anti-
pS63c-Jun, c-Jun, and phospho-MAPKAPK-2(Thr222) antibody; Millipore, anti-
MT1-MMP mAb (MAB3328), anti-cortactin (p80/85) antibody (4F11), Alexa 
Fluor® 488; Santa Cruz Biotechnology, Inc., anti-JNK rabbit pAb; Invitrogen, 
diaminophenylindole (DAPI), and rhodamine phalloidin; Jackson 
ImmunoResearch Laboratories, HRP-conjugated secondary antibodies; LC-LABs, 
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SP600125, U0126, SB203580; Advanced BioMatrix, PureCol type I bovine 
collagen solution (3.2 mg/ml); PeproTech, TGFβ1; R&D systems, anti-
TGFβ (1,2,3) antibody (MAB1835)  
4. Cell culture in three-dimensional type I collagen gels  
 3D collagen type I gels for cell culture were prepared using PureCol type I bovine 
collagen (Advanced BioMatrix, Poway, CA) in 24-well culture plate.  Collagen I 
mixtures (2.5 mg/ml) were made by adding the appropriate volumes of 10x 
reconstitution buffer (260 mM sodium bicarbonate and 200 mM HEPES), 10x 
RPMI (Sigma Aldrich) to the purchased collagen 1 solution, with slowly and gently 
pipetting up and down.  To adjust the pH of the collagen I solution mixture, we 
used the ice-cold solution of 2 N NaOH and measured the pH of the neutralized 
collagen with pH paper strip.  The pH must be in the range of 7.2 to 7.4.  The 
neutralized solution of collagen I was incubated on ice for 3 to 5 min to allow the 
pH of the solution to be equilibrated, and then centrifuged at 10,000 g for 3 min to 
get rid of air bubbles at 4°C.  The bottom layer of 2.5 mg/ml collagen I was made 
in each well with 30 µl and allowed to gel by incubation for 30 min at 37°C.  Top 
layer that cell suspension containing 300,000 cells was mixed with the 150 µl 
neutralized collagen I mixture was loaded onto the bottom layer, and allowed to gel 
by incubation for 30 min at 37°C.  In cases, three-dimensional Matrigel (BD 
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Biosciences) or a mixture of Matrigel™ and type 1 Collagen ( t a ratio of 5 mg/ml 
to 1.25 mg/ml) was also prepared by the same procedure as above. Media with 10% 
FBS was then overlaid on top of the gel with or without SP600125 (50 µM) for 24 
to 72 h. The medium was replaced every other day. In case, pH-controlled media 
(using filter 1N HCl) with 10% FBS was replenished every day for 2 days after the 
embedding, or hypoxic condition at 5% 5% O2 was applied for 4 h after the 
embedding, in parallel to the normal condition.   
5. Immunoblottings 
Whole cell lysates from 2D cultures were prepared, as described previously [84].  
To obtain the whole cell lysates from 3D collagen cell cultures, cells embedded 
into 3D collagen I and cultured for 3 days were transferred into ice-cool 1.5 ml 
tubes from 24-well culture plate using truncated-pipette tips and spun down for 1 
min at 2,500 g to remove residual medium and collagen at 4°C.  Cell pellets 
within collagen masses were washed with ice-cold PBS and then solubilized in a 
modified RIPA (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, and 0.25% sodium 
deoxycholate) with a protease inhibitor cocktail (GenDepot, USA) homogenizing 
with truncated pipette tips once every 20 min for 60 min on ice.  The extracts 
were centrifuged at 15,000 g for 30 min at 4°C and then the lysate was collected 
from the supernatant.  The obtained whole extracts were diluted with 4x SDS 
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polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer and boiled at 
100°C for 10 min.  Because of the presence of the collagen I, protein 
concentrations could not be used to normalize the protein amount in the lysates.  
The lysates at an equal sample volume were initially loaded for α-tubulin levels by 
standard Western blotting.  Based on the intensities of α-tubulin bands in the 
experimental conditions, the samples were normalized for equal protein loading in 
standard Western blots. 
6. RT-PCR and quantitative real time PCR (qPCR) 
Total RNA was extracted from cells in 3D collagen I gels using TRIzol (Invitrogen) 
according to the manufacturer’s protocol.  One µg of total RNA was reverse 
transcribed using amfiRivert Platinum cDNA Synthesis master mix (GenDepot, 
USA), and qPCR was performed using DreamTaq Green PCR Mater Mix (Thermo 
Scientific) and 7900HT Fast real time system (Applied Biosystems).  Primers for 
Snail1, Cortactin, JNK1, Smad2/3, Twist, Snail2/Slug and GAPDH mRNA were 
designed using Primer3 software. Primer sequences were as follow: CDH1(E-
cadherin), forward 5’-TGCCCAGAA AAT GAAAAAGG-3’ and reverse 5’-
GTGTATGTGGCAATGCGTTC-3’ ; CTTN(cortactin), forward 5’-CCTGGAA 
ATTCCTCATTGGA-3’ and reverse 5’-CACAAAATCAGGGTCGGTCT-3’; JNK1, 
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forward 5’-TTGGAACAC CATGTCCTGAA-3’ and reverse 5’-ATGTACGG 
GTGTTGGAGAGC-3’; Snail1, forward 5’-GGTTCTTCTG CGCTACTGCT-3’ and 
reverse 5’-TAGGGCTGCTGGAAGGTAAA-3’; Smad2, forward 5’-CGAAATGC 
CACGGTAGAAAT-3’ and reverse 5’-CCAGAAGAGCAGCAAATTCC-3’; Smad3, 
forward 5’-CCCCAGAGCAATATTCCAGA-3’ and reverse 5’-GGCTCGCAG 
TAGGTAACTGG-3’; Twist, forward 5’- GGAGTCCGCAGTCTTACGAG-3’ and 
reverse 5’-TCTGGAGGACCTGGT AGAGG-3’; Snail2/slug, forward 5’-GGGGA 
GAAGCCTTTTTCTTG-3’ and reverse 5’-TCCTCATGTTTGTGCA GGAG-3, 
GAPDH, forward 5’-GAGTCAACGGATTTGGTCGT-3’ and reverse 5’- 
GACAAGCTTCCCGTTCTC AG-3’. 
7. 3D immunofluorescence analysis 
Cells were cultured within Polydimethylsiloxane prepolymer (PDMS) glass 
coverslip and fixed directly with 4% formaldehyde for 30 min at room temperature 
(RT), and subsequently treated with 100 mM glycine to quench residual aldehyde 
groups.  After PBS washing, cells were permeabilized for 30 min with 0.5% 
Triton X-100 at room temperature (RT) and blocked for 2 h with PBS in 3% BSA.  
Some cells were stained with either fluorescein-labeled phalloidin (Molecular 
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Probes, 1:250) or Alexa Fluor® 488-labeled anti-cortactin (Millipore, 1: 200) at 
4°C overnight.  Cells were then washed with washing buffer (PBS in 130 mM 
NaCl, 13 mM Na2HPO4, 3.5 mM NaH2PO4, pH 7.4).  Nuclei were counterstained 
with diaminophenylindole (DAPI; Molecular Probes).  Confocal images were 
captured using a confocal microscope with a Nikon Plan-Apochromat 60x/1.4 N.A. 
oil objective (Nikon eclipse Ti; NiKon, Japan) and analyzed using the NIK 
software or IMARIS imaging software (Bitplane AG, Zurich, Swiss). 
8. Chromatin immunoprecipitation (ChIP) analysis 
The MDA-MB-231 cells were embedded in 3D collagen I and cultured in the 
absence (control) or presence of SP600125 (50 µM) for 3 days.  Cell culture 
media were sucked out and cells in 3D collagen I were fixed with 3.7% 
formaldehyde for 30 min at RT and washed with 100 mM glycine addition and 
PBS.  The fixed cells were transferred 1.5 ml centrifuge tube on ice and washed 
with ice-cold PBS including protease inhibitor cocktails and spun down at 5,000 ×g 
for 1 min at 4°C.  The supernatants were removed and the cells were lyzed with 
SDS buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1 and 1 mg/ml each of 
aprotinin, leupeptin, and pepstatin A) on ice.  Samples were sonicated on ice (5 
sec each time at intervals of 10 sec for 1 min; Ultrasonic sonicator) to homogenize 
cells in the collagen gel, and spun down at 15,000 ×g for 3 min at 4°C to remove 
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collagen I rest prior to collection of the supernatants.  Aliquoted supernatants (400 
µl) were sonicated on ice to fragment DNA to 200 ~ 1,000 base pair length and 
centrifuged at 15,000 ×g for 20 min at 4°C. The sonicated samples were diluted 10-
fold in ChIP buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris, 
pH 8.1, 167 mM NaCl, and 1 mg/ml each of aprotinin, leupeptin, and pepstatin A).  
The diluted chromatin solutions (400 µl) were incubated with 10 µl antibody of 
either anti-pS63c-Jun, anti-Smad2, anti-Smad3 (Cell Signaling Tech.), or anti-Snail1 
antibody (Santa Cruz Biotech. Inc.) at 4°C with rotation overnight.  Before 
immunoprecipitation, 400 µl of chromatin solution was saved (input chromatin).  
The immune complexes were collected by adding 50 µl of salmon sperm 
DNA/protein A and G-beads and rotating for 4 h at 4°C.  The beads were 
recovered by brief centrifugation, washed with low salt complex wash buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), 
high salt complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM 
Tris-HCl, pH 8.1, 500 mM NaCl), LiCl immune complex buffer (0.25% LiCl, 1% 
NP-40, 1% sodium deoxycholate, 1 mM EDTA, 1mM EDTA, 10 mM Tris-HCl, pH 
8.1), and TE (20 mM Tris,  1 mM EDTA), pH 8.0, buffer with a brief 
centrifugation between each wash to recover the beads.  The immune complexes 
were eluted from the beads by the addition of 500 µl 1% SDS in 0.1 M NaHCO3 to 
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the bead pellet, voltexing and rotating at 4°C for 10 min.  To reverse the cross-
linking process, 200 mM NaCl was added to the eluates before incubation at 65°C 
overnight.  Incubation at 55°C for 1 h was done within 10 mM EDTA, 40 mM 
Tris-HCl, pH 6.5, and 2 ml of 10 mg/ml proteinase K.  DNA was recovered by 
phenol/chloroform extraction and ethanol precipitation.  Promoter sequences were 
detected in immunoprecipitated and input DNA by PCR using specific primers; 
primer for snail1 gene; forward1, 5’-TCCAAACTCCTACGAGGC-3’ and reverse1, 
5-GAAGAAGTGGCAACTGCT-3, forward2, 5’-AGCAGTTGCCACTTCTTC-3’ 
and reverse2, 5’-GCAAAGGGAAGTGTGCTT-3’, forward3, 5’- GGAGACG 
AGCCTCCGATT-3’ and reverse3, 5’-CAGTAGCGCAGAAGAACCACT-3’, 
primer for negative control regions, forward 5’-CGTAAACACTGGATAAG G-
3‘ and reverse 5’-GGAAACGCACATCACTGG-3’, primer for the cortactin (CTTN) 
gene; forward  5’-TCTGCAGACTCGCCACAG-3‘ and reverse 5’-CAGG 
CACCAGGCTCTACTTC-3‘ primer for negative control regions, forward 5’-
AGTGTTATGATTACA GGC-3‘ and reverse 5’-ATAGAGCACAGCGAAGAC-3’, 
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primers for the snail1; forward 5’-AGCA CACTTCCCTTTGCATT-3’ and reverse 
5’-CACCCGTTCCTTCCCTTATC-3’ 
9. Time-lapse imaging 
Time-lapse cell images in 3D type 1 collagen gel were captured with IX81-ZDC 
(Olympus) for 24 h.  The cells embedded in 3D collagen I gels were cultured in 
the absence (control) or presence of 50 µM SP600125 in PDMS glass coverslips.  
In some cases, cells expressing GFP or mCherry protein imaged with a Nikon 
eclipse Ti microscope (Nikon) with a Nikon Plan-Apochromat 60X/1.4 N.A. oil 
objective.  All microscopes were equipped with a Chamlide Incubator systems 
(LCI live cell instrument, Korea), and an environmental chamber mounted on the 
microscope maintained constantly at 37°C, 5% CO2 and 95% humidity. 
10. Immunohistochemistry 
The corresponding whole-mount slides were used for validation of immunoblotting 
data by immunostaining for snail1, pS63-c-Jun (cell signaling) and cortactin (BD, 
bioscience). Sections (4 µm) of paraffin-embedded tissue were deparaffinized and 
rehydrated. After treatment with 3% hydrogen peroxide for 10 min to block 
endogenous peroxidases, the sections were boiled in 10 mM citrate buffer (pH 6.0) 
６９ 
in a microwave oven for 20 min. The sections were subsequently incubated at 4°C 
overnight with the aforementioned primary antibodies. After thorough rinsing in 
phosphate-buffered saline, the sections were processed using the DAKO LSAB 
streptavidin-biotin labeling kit, stained with amino-ethyl carbazole, and 
counterstained with Mayer’s hematoxylin.  
11. Statistical Methods 
Student’s t-tests were performed for comparisons of mean values to determine 











1. Diverse tumor microenvironmental factors revealed a correlationship 
among JNKs inactivation, Snail1 induction, and cortactin suppression.    
To mechanistically investigate migratory and invasive behaviors of tumor cells 
embedded in a 3D environment, we cultured MDA-MB-231 breast cancer cells in 
3D collagen gel with 10% serum under different environmental parameters to 
promote continuous tumor cell growth showed reduced Ser63 phosphorylation 
levels of c-Jun (i.e., pS63c-Jun), although proliferating cell nuclear antigen (PCNA) 
was not changed to indicate no significant cytotoxicity during the culture (Fig. Ⅲ-
2A). Concomitantly, Snail1 expression increased but cortactin expression 
decreased, although Snail2/Slug and c-Jun levels were unchanged (Fig. Ⅲ-1A). 
The increased Snail1 and decreased pS63c-Jun and cortactin levels depended on 
cell densities, since continuous culture at a high cell density showed more dramatic 
changes, compared with less cells (Fig. Ⅲ-2B). We then found that extracellular 
acidity caused the same effect (Fig. Ⅲ-2C). Acute hypoxia with an HIF1α 
induction showed also the same effect (Fig. Ⅲ-2D). Furthermore, breast tumor 
tissues showed Snail1 immunostaining in a random distribution around the distal 
and proximal edges of a large invasive tumor nest (Fig. Ⅲ-2E, top), compared with 
pS63c-Jun and cortactin expression at the invasive tumor edges (Fig. Ⅲ-2E, 
bottom). These interestingly suggest an exclusive relationship between Snail1 and 
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cortactin for invasion JNK inhibition caused Snail1 induction and cortactin 















Fig. Ⅲ-2. Diverse tumor microenvironmental factors caused JNK signaling 
inactivation, Snail1 induction, and cortactin suppression. (A to D) Whole cell 
lysates were prepared from MDA-MB-231 cells embedded in 3D collagen gels 
with the normal serum-containing culture media refreshment every day for upto 5 
days (A) and upto 4 days of culture at lower or higher densities (B), in different-pH 
medium that was replenished every day (C), in hypoxic condition for 4 h (D). N 
depicts normoxia and H depicts hypoxia. Cell lysates were processed for standard 
immunoblotting to analyze the indicated molecules. Data represent three 
independent experiments. (E) Breast cancer tissues were immunostained for Snail1, 
pS63c-Jun, and cortactin in human breast cancer tissues (magnifications of 100×, 








2. Inhibition of JNK signaling caused Snail1 induction and cortactin 
suppression, leading to reduced migration and invasion in 3D collagen gels 
We next examined the morphology and behavior of MDA-MB-231 cells 
embedded in 3D collagen gels. Pharmacological JNKs inhibition by SP600125 
treatment caused an elongation in cellular morphology (Fig. Ⅲ-3A), with a higher 
length/width ratio (Fig. Ⅲ-3B). However, MDA-MB-231 cells embedded in 3D 
Matrigel or a mixture of Matrigel and collagen (at a 4:1 w/w ratio) did not show the 
elongation, indicating an ECM-specific morphological effect (Fig. Ⅲ-4A). RT-
PCR and immunoblotting after JNK inhibition showed that Snail1 and Twist 
mRNAs expression increased, but cortactin mRNA decreased, although 
Snail2/Slug mRNA level was not changed (Fig. Ⅲ-3C). More importantly, the 
Snail1 mRNA levels were not correlated with E-cadherin (CDH1) level, indicating 
that the Snail1 might not be linked to E-Cadherin suppression (Fig. Ⅲ-3C). These 
gene expression changes occurred in the cells embedded only in collagen gel but 
not Matrigel or the mixture of Matrigel and collagen I. Phosphorylated-ERKs and -
p38 were not involved in the effects on alterations in gene expression, because 
there were no similar changes upon JNK inhibition (Fig. Ⅲ-3D). SP600125 
treatment did not alter actin nucleator Arp2 and mDia expression levels, either (Fig. 
Ⅲ-4D). Thus, the morphological elongation by JNK inhibition might be correlated 
with the alterations in expression levels of Snail1 and Cortactin. Live cell imaging 
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was used to monitor morphological changes and/or motility upon treatment with or 
without SP600125. Cells by JNKs inhibition exhibited relatively-steady locations 
and morphological protrusions during time-lapse imaging, whereas control cells 
showed dynamic growth of invasive protrusions (Fig. Ⅲ-3E) leading to more 
consistent migration in 3D collagen gels (Fig. Ⅲ-3F). Therefore, it is possible that 
JNK inhibition-mediated effects may control migratory and invasive properties of 
















Fig. Ⅲ-3. Inhibition of JNK signaling caused Snail1 induction and cortactin 
suppression, leading to less dynamic MDA-MB-231 cell migration and 
invasion within 3D collagen gels. (A and B) Images of elongated morphology of 
MDA-MB-231 cells in 3D collagen gels after pharmacological inhibition of JNK 
signaling for 3 days were saved (A) and quantified to get length/width ratio using 
imaging software (B). (C) RT-PCR analysis from the cells embedded in 3D 
collagen gels and treated with 50 μM SP600125 for different times. P depicts a 
positive control. (D) Immunoblots were performed using whole lysates of cells 
embedded in 3D collagen gels and treated with SP600125 (SP) at different 
concentrations for 24 h. (E and F) Time-lapse microscopic images of the cells 
embedded in 3D collagen gels and treated with vehicle (DMSO, Control) or 50 μM 
SP600125. Arrow head in the control condition indicates dynamically and 
invasively growing tips (E). Tracking analysis of each control cell showed dynamic 
migration for longer distances (Con, n = 7), but SP600125 treated cells exhibited 








Fig. Ⅲ-4. JNK signaling inhibition, but not ERKs or p38 signaling inhibition, 
in cells embedded in 3D collagen I (but not Matrigel-containing) gels caused 
increases in Snail1 expression and decreased cortactin expression. (A) MDA-
MB-231 cells embedded in Matrigel did not show morphological changes upon 
SP600125 treatment. (B) SP600125 treatment to MDA-MB-231 cells embedded in 
3D collagen I gel and cultured for 3 days , but not in Matrigel or a mixture of 
Matrigel and collagen I gel (at a ratio of 5 mg/ml to 1.25 mg/ml), resulted in an 
increased Snail1 expression. (C) JNK signaling inhibition (i.e., decreased pS63c-
Jun) by SP600125 treatment to MDA-MB-231 cells embedded in 3D collagen I gel 
resulted in increased Snail1 and decreased cortactin expression without affecting 
ERKs and p38 activities. (D) JNK signaling inhibition, but not ERKs and p38 
signaling inhibition, resulted in increased Snail1 expression and decreased cortactin 
expression without effects on mDia and Arp2 expression that are involved in actin 







3. JNK inhibition caused less efficient formation of actin and cortactin-
enriched invadopodia.  
When we costained cells with cortactin and F-actin, which are known to localize 
at the invadopodia [85], software-based z-stacked 3D images following staining 
with Alexa488®-tagged anti-cortactin (green) and phalloidin (red) clearly showed 
more yellowish overlapped spots (i.e., invadopodia) in control, vehicle-treated cells. 
This is demonstrated by the green and the red overlapping peaks in the histogram 
representing the intensity profile throughout the xz cut-stack (white dotted line, Fig. 
Ⅲ-5). However, SP600125-tretaed cells did not show such overlaps, leading to less 
green and red overlapped peaks in the histogram (Fig. Ⅲ-5B). We also observed 
dynamic turnover in GFP-cortactin localization along the frequently altered 
boundaries of control cells, whereas its localization in SP600125-treated cells was 
steady and not at the cellular boundary.  Human breast cancer cell lines cultured 
on 3D-laminin-rich ECM gels are grouped into four different morphological 
classifications: round, mass, grape-like, and stellate [86]. When diverse breast 
cancer cell lines were tested for the JNK inhibition-mediated effects in the 3D 
collagen I environment, mass (T-47D and MCF-7) or grape-like (MDA-MB-468) 
cells did not show morphological elongation, whereas stellate cells (MDA-MB-436 
and MBA-MB-231 cells) showed morphological elongation with a loss of 
cortactin- and actin-colocalized spots (yellow spots) upon JNK inhibition (Fig. Ⅲ-
８１ 
5C). Further, like MDA-MB-231 cells, MDA-MB-436 cells decreased pS63c-Jun, 
increased Snail1 expression, and decreased cortactin expression upon JNK 
inhibition (Fig. Ⅲ-5D). These observations support that certain breast cancer cells 
(i.e., stellate-grouped cells) could become less invasive by the signaling link 
















Fig. Ⅲ-5. JNK inhibition-mediated effects among different breast cancer cell 
lines. (A and B) Snap images [A and B] and 3D-stacked fluorescent images of 3D 
rendition (with x, y, and z axes) are shown for confocal fluorescent images of 
MBA-MB-231 cells treated with DMSO (vehicle, Control, A) or SP600125 (B). 
Each xz or yz plane of a confocal slice is shown separately and fluorescent 
intensities throughout the white-arrow sections in each plane are represented as 
histograms in the right side. The xz or yz planes (white-dotted boxes and white 
arrows) were the stacks for fluorescence intensity profiles through the layers and 
their fluorescence histograms throughout the white-arrowed section were shown to 
clearly demonstrate the overlap among green and red, but not blue, fluorescence. 
Cortactin is green, nucleus is blue, and F-actin is red. (C to E) Different breast 
cancer cells embedded in 3D collagen were analyzed for F-actin (red), cortactin 
(green), and nucleus (DAPI) using confocal microscopy at confocal slices (C), or 







4. Snai1l expression decreased invadopodia formations and caused the inverse 
relationship between Snail1 and cortactin expression 
When Snail1 was overexpressed, cortactin was reduced, but pS63c-Jun was not 
changed (Fig. Ⅲ-6A), suggesting c-Jun upstream of Snail1. Overexpression of 
Snail1 (marked by cotransfected mCherry plasmid) decreased cortactin-enriched 
spots, compared with mCherry alone-transfected control or exogenic Snail1-
negative (i.e., only greenish) cells showing more frequent cortactin-positive spots 
(Fig. Ⅲ-6B, C). More cortactin was located around cellular boundaries of the 
control cells, whereas Snail1-overexpressing cells showed more perinuclear 
cortactin localizations. Following transfection with siSnail1, CTTN mRNA 
increased and JNK1 mRNA were not changed (Fig. Ⅲ-6D). The JNK inhibition-
mediated decrease in cortactin expression was abolished by knockdown of Snail1 














Fig. Ⅲ-6. JNK inhibition-mediated snail1 expression caused also an inverse 
relationship between Snail1 and cortactin and decreased actin and cortactin-
enriched invadopodia formation. (A to C) Immunoblots (A) or 3D-stacked 
images of 3D rendition (B and C) were processed from MDA-MB-231cells 
transiently transfected with empty plasmid (-) or plasmid encoding Snail1 WT 
together with plasmid encoding GFP or mCherry to mark the transfectants (red, B 
and C). Note that mCherry/Snail1 WT-cotransfected cells (bottom, red arrow) 
showed less cortactin-enriched spots, compared with cells transfected with 
mCherry plasmid alone. The xz planes (white-dotted boxes) of confocal slices 
represent cut-layers for green fluorescence intensity profiles, and fluorescence 
histograms along the white-arrow sections are shown to illustrate the green 
fluorescence peaks. (D and E) RT-PCR (D), immunoblots (E) of cells embedded in 
3D collagen gels treated with vehicle (-) or SP600125 (SP) after transient 
transfection with siRNAs against control sequence (siCon) or Snail1 (siSnail1). 






5. The relationship among pS63c-Jun, Snail1, and cortactin occurred at 
transcriptional level.  
We next tested whether these molecular changes occurred at the transcriptional 
level by chromatin immunoprecipitation (ChIP) assay. There found AP1 binding 
sites in the human Snail1 gene promoter region and E-box binding sites in the 
human cortactin (CTTN) gene promoter region (Fig. Ⅲ-7A). Chromatin extracts, 
prepared cells in 3D collagen gel in the presence of SP600125 treatment with 
enhanced Snail1 and reduced pS63c-Jun and cortactin levels (Fig. Ⅲ-7B), were 
immunoprecipitated with either anti-pS63c-Jun or anti-Snail1 antibody (Fig. Ⅲ-7C, 
D). PCR product representing region p1 of the Snail1 promoter (Snail1-p1), but not 
a control region (i.e., a non-AP1-binding site, Snail1-n), was only detected from 
pS63c-Jun immunoprecipitated chromatin (Fig. Ⅲ-7C), indicating a binding of 
pS63c-Jun to the Snail1 promoter region. However, there may be other factors 
involved in Snail1 transcription because reduced pS63c-Jun correlated with 
enhanced Snail1 mRNA levels (see below). Meanwhile, chromatin precipitated 
with anti-Snail1 antibody showed more PCR product representing region p of the 
CTTN promoter (cortactin-p), but not from a control region in the promoter 
(cortactin-n), in SP600125-treated cells (Fig. Ⅲ-7D). Snail1, a transcriptional 
suppressor [59], could thus bind a promoter region of the CTTN gene and suppress 
cortactin expression. RT-PCR revealed that Snail1 mRNAs were more stable in 
８９ 
control cells (treated with actinomycin D alone) than cells treated with actinomycin 
D and SP600125 together (Fig. Ⅲ-7E). Quantitative real time PCR (qPCR) 
analysis showed that CTTN mRNA had a half-life longer than 48 h in control cells, 
but a half-life of approximately 24 h in cells treated with both actinomycin D and 
SP600125 (Fig. Ⅲ-7F). The half-lives of Snail1 and cortactin proteins were < 6 h 
for Snail1 and ≅ 12 h for cortactin, being independent of SP600125 treatment (Fig. 
Ⅲ-7G). pS63-c-Jun binding to a Snail1 gene promoter region occurred without 
SP600125 treatment. Thus, increased Snail1 transcript upon JNK inhibition 














Fig. Ⅲ-7. The relationship between pS63c-Jun, Snail1, and cortactin occurred 
at the transcriptional level. (A) Schematic presentations of AP1-binding domains 
in the promoter region of the Snail1 gene (top) or E-box binding element in the 
promoter regions of the CTTN gene (bottom). (B to D) ChIP assay using chromatin 
immunoprecipitates using anti-pS63c-Jun antibody (C) or anti-Snail1 antibody (D) 
prepared from whole cell lysates (WCL, B) of cells treated with vehicle (-) or 
SP600125 (SP, +) in 3D collagen gels. (E and F) RT-PCR analysis for Snail1 or 
cortactin (E) or quantitative RT-PCR for cortactin (F) from the cells treated with 
DMSO or SP600125 with or without actinomycin D (ActD). (G) Immunoblotting 
for Snail1 or cortactin from the cells treated with DMSO or SP600125 with or 









6. Snail1 induction by JNKs inhibition enhanced by TGFβ1/Smad signaling. 
Snail1 mRNA increased but CTTN mRNA decreased in cells cultured for 3 days in 
3D collagen gel, whereas Smad2 and Smad4 mRNA was not altered (Fig. Ⅲ-8A), 
indicating that cells embedded in 3D collagen gel may secrete TGFβ1 leading to 
autocrine effects. However, immunoblottings showed increased TGFβ1, Smad2, 
and Smad3 protein levels and Smad2 phosphorylation (Fig. Ⅲ-8B). JNK inhibition 
or extracellular acidity also enhanced TGFβ1 and Smad2 expression (Fig. Ⅲ-8C, 
D). Cells were then analyzed for Snail1 and cortactin expression after transfection 
with shRNA against GFP or each Smad. The JNK inhibition-mediated changes in 
Snail1 and cortactin expression were blocked by Smad2 or Smad4 knockdown, 
whereas Smad3 knockdown did not block the changes (Fig. Ⅲ-8E). SP600125-
treated cells showed Smad-binding element in the Snail1 gene promoter region 
(Snail1-p3), as demonstrated by RT-PCR amplification of chromatin precipitated 
using anti-Smad2 or -Smad4 (but not -Smad3) antibodies (Fig. Ⅲ-8F), suggesting 
that TGFβ1/Smad activity in MDA-MB-231 cells embedded into 3D collagen gel 






Fig. Ⅲ-8. Enhanced TGFβ1/Smad signaling in 3D collagen gel was responsible 
for increased Snail1 transcription upon JNK signaling inhibition. (A to D) RT-
PCR (A) or immunoblotting analysis (B to D) for the indicated molecules in MDA-
MB-231 cells cultured in 3D collagen upto 5 days (A and B) or for 24 h (C and D), 
treated with vehicle (DMSO, Con) or SP600125 (SP) (C), or with culture media 
replenished every day at different pH (D). (E) Immunoblots using lysates from the 
cells treated with DMSO (-) or SP600125 (+) after transient transfection of shGFP 
or shRNA against each Smad protein (shSd). (F) Schematic presentations of the 
Smad-binding element in the promoter regions of the Snail1 gene (top) and ChIP 
assay using chromatin immunoprecipitates using anti-Smad antibodies (bottom) 
prepared from whole lysates of cells treated with vehicle (-) or SP600125 (+) in 3D 








7. Specific JNK1 inactivation or suppression reduced pS63c-Jun and cortactin 
and enhanced Snail1 expression.  
To avoid nonspecific effects by SP600125, cells were transfected with GFP 
plasmids (to mark transfectants during imaging) together with or without 
dominant-negative (DN) JNK1. DN-JNK1 expression reduced pS63c-Jun, 
enhanced Snail1, decreased cortactin expression (Fig. Ⅲ-9A), and less actin-
enriched spots (shown as peaks in the histogram, Fig. Ⅲ-9B). When JNK1 was 
suppressed by siRNA introduction, the relationship among JNK1, Snail1, and 
cortactin levels were similar to those found in MDA-MB-231 cells continuously 
cultured in 3D collagen gels with SP600125 treatment (Fig. Ⅲ-9C, D). Further, 
siJNK1-transfected cells [marked with cotransfected GFP-tagged control siRNA as 
a green spot marked with a white arrow showed reduced actin-enriched spots, 
compared with untransfected neighboring cells (i.e., siJNK1-negative cell without 











Fig. Ⅲ-9. JNK1 suppression caused an inverse relationship among Snail1 and 
cortactin expression and resulted in decreased invadopodia formation. (A and 
B) Immunoblots (A) or 3D-stacked images of 3D rendition (B) were processed 
from cells transiently transfected with empty plasmid (-) or plasmid encoding DN-
JNK1 together with pEGFP (GFP) plasmid to mark the transfectants (green, B). 
The yz planes (white-dotted boxes) of confocal slices represent cut-layers for 
fluorescence intensity profiles, and fluorescence histograms corresponding to a 
section throughout the layers (white-dotted arrow) are shown to illustrate the red 
fluorescence peaks. (C and D) RT-PCR (C) or immunoblots (D) of cells embedded 
in 3D collagen gels after transient transfection with siRNAs against GFP (siGFP) 
or JNK1 (siJNK1). (E) Confocal fluorescent images (slices) of cells cotransfected 
with siJNK1 and GFP-tagged siControl [to mark siJNK1-transfectants, green spot 
(arrow)]. GFP-siControl plus siJNK1 is green, F-actin is red, and nucleus is blue. 







8. JNK1 inactivation caused localization of MT1-MMP at perinuclear 
regions but not membrane boundaries.  
When actin and collagen fibers were stained or visualized, control cells showed 
clear ECM-degraded areas (yellow arrow heads), whereas SP600125-tretaed cells 
showed no clear ECM-degraded areas (Fig. Ⅲ-10A). We then imaged the 
invadopodia using a different marker, matrix metalloproteinase MT1-MMP [85]. 
When cells transfected with mCherry tagged MT1-MMP were embedded into 3D 
collagen gel before double-staining for MT1- MMP (red) and actin (green), MT1-
MMP was overlapped with actin-enriched spots, as demonstrated by frequent 
overlapping throughout the xz or yz cut-stacks (Fig. Ⅲ-10B). MDA-MB-231 cells 
embedded in 3D collagen gels did not exhibit changes in MT1-MMP expression, 
unlike cortactin (Fig. Ⅲ-7C, D). When mCherry-tagged MT1-MMP was 
transfected into cells, the vehicle-treated control cells showed dynamic turnover of 
MT1-MMP-positive spots along peripheral and/or central regions of the cells, 
frequent alterations in morphological boundaries, and led to enhanced cellular 
locomotion (Fig. Ⅲ-10C, Supplementary movie 3), However, SP600125-treated 
cells showed a steady morphology and more stable invadopodia with greater 
intensities for MT1-MMP (Fig. Ⅲ-10D). Cells cotransfected with mCherry-MT1-
MMP and GFP-cortactin showed dynamic translocation of spots doubly-positive 
for cortactin and MT1-MMP (i.e., yellowish spots) along the cellular boundaries 
９９ 
(arrow heads, Fig. Ⅲ-10E), whereas the cortactin and MT1-MMP double-positive 
spots in SP600125-treated cells were more localized around the nucleus than cell 


























Fig. Ⅲ-10. Cortactin and MT1-MMP were enriched at the membrane 
boundaries of cells embedded in 3D collagen in a manner that was dependent 
on JNK signaling. (A) Cells in 3D collagen were stained for actin (red) and 
visualized at confocal slices for FITC-collagen I fibers (green) to see dark ECM-
degraded regions (arrowheads) in the presence of DMSO or SP600125 treatment. 
Yellow arrowheads indicated the dark area after collagen I degradation (as shown 
in xz-plane at a confocal slice), whereas white arrowheads in 600125-treated cells 
showed overlappings of actin and collagen I without degradation of collagen I (not 
to be dark in xz-plane). (B to D) Cells were transiently transfected with plasmid 
encoding mCherry-tagged MT1-MMP for 2 days and embedded into 3D collagen 
gels before immunostaining for MT1-MMP (red) and actin (green) (B) or before 
live imaging for upto 4 h in the presence of DMSO (Control, C) or SP600125 (D) 
treatment using confocal fluorescent microscopy with controlled temperature and 
CO2. (B) The xz or yz planes (white dotted boxes) of confocal slices represent cut-
layers for fluorescence intensity profiles, and their fluorescence histograms along 
white-arrow sections are shown to illustrate the overlap between green and red 
fluorescence, but not blue fluorescence (DAPI). (C and D) Sky-blue dotted boxes 
mark the regions for the snap images and white-dotted lines indicate cellular 
boundaries to show alterations in cell morphology. Note that MT1-MMP positive 
spots in control cells show dynamic turnover along the membrane boundary (B), 
whereas the spots in SP600125-treated cells are stable and lack frequent turnovers 
１０４ 
(C) as shown in some cases via colorful arrowheads. These snap images were from 
Supplementary Movies 3 (Control) and 4 (SP600125-treated). The data represent 
three isolated experiments. (E and F) The MDA-MB-231 cells were transfected 
with plasmid encoding mCherry-tagged MT1-MMP and GFP tagged cortactin, 
embedded into 3D collagen gels and treated with vehicle (DMSO, Control, E) or 
SP600125 (F) prior to imaging for MT1-MMP (red) and cortactin (green). Arrow 
heads indicate regions along the membrane boundary where both cortactin and 
MT1-MMP localized together (B). Note that costained spots (yellow) are enriched 
in perinuclear regions of the cells treated with SP600125 (C), compared with 











 This study revealed that the environmental parameters around tumor cells 
including cell density, extracellular acidity, and hypoxia could cause JNK signaling 
inactivation (i.e., decreased c-Jun phosphorylation), TGFβ1/Smad signaling 
activation, Snail1 induction, and cortactin suppression.  This signaling network 
led to stabilized localization of cortactin and MT1-MMP (both proteins are 
invadopodia markers) at perinuclear regions rather than at cell membrane 
boundaries, resulting in the reduced formation of actin and cortactin-enriched 
invadopodia along the edges of cells embedded in 3D collagen gels.  We have 
compared the invasive features of MDA-MB-231 breast cancer cells embedded in 
either 3D collagen gels, 3D Matrigel, or a mixture of Matrigel and collagen I (at a 
4:1 w/w ratio).  Cells embedded in 3D Matrigel or the mixture of Matrigel and 
collagen I did not exhibit the JNK, Snail1, cortactin linkage demonstrated in cells 
in 3D collagen gels.  A specific communication between MDA-MB-231 cells and 
surrounding ECM types appeared to regulate invasive behaviors. Among the 
diverse morphologically-different breast cancer cells [87], only stellate cells 
(MDA-MB-231 and MDA-MB-436) showed JNK activity-dependent 
morphological elongation and signaling network change, leading to a decreased 
invadopodia formation, indicating that invasiveness in certain types of breast 
cancer may be regulated by the JNK, Smads, Snail1, and cortactin network. 
１０６ 
However, Mass grouped cells (T-47D and MCF-7) that have been established from 
IDC tumors [87], did not show the JNK-dependent effects on snail1 induction and 
cortactin suppression.  Consistent with increased Snail1 stains approaching the 
central necrotic area of ductal carcinoma in situ (DCIS) [88], here Snail1 was 
randomly expressed in clinical breast tumor tissues rather than being localized 
around the invasive edges. The JNK, Smads, Snail1, and cortactin signaling 
network may thus be related to noninvasive DCIS. Snail1 induces EMT by 
suppressing E-cadherin [15, 89], being associated with the metastatic potential of 
infiltrating ductal carcinoma (IDC) [90, 91].  However, in DCIS, Snail1 is also 
localized in the nucleus, being correlated with higher tumor grade and proliferation 
rather than with migration [88], and expressed at similar levels in both the tumor 
and the normal zone of DCIS tissues [92]. Therefore, Snail1 expression may have 
differential effects on metastasis depending on the local invasiveness. In this study, 
Snail1 induced by JNKs inhibition was not correlated with E-cadherin (CDH1) 
mRNA suppression.  Instead, Snail1 bound the promoter of Cortactin (CTTN) and 
negatively regulated its expression. Snail1 may thus have different downstream 
targets leading to less metastatic potential in DCIS (an early noninvasive breast 
cancer), rather than leading to E-cadherin suppression and enhanced migration and 
invasion in IDC.  Indeed, hypoxia-mediated Snail1 expression in breast cancer 
cells did not enhance migration, following a partial hypoxia-induced EMT 
phenotype [88].  In control MDA-MB-231 cells in 3D collagen gels, pS63c-Jun 
１０７ 
bound to the promoter of the Snail1 gene, indicating that active c-Jun may regulate 
basal Snail1 transcription.  However, in the conditions where pS63c-Jun decreased 
via the influence of extracellular environments, Snail1 mRNA and protein levels 
increased, indicating that proteins others than c-Jun could be involved in Snail1 
transcription.  Inhibiting JNK activity in E12.5 lung explants causes TGFβ1-
activated Smad2 phosphorylation and gene expression changes for branching 
morphogenesis [93].  C-Jun associates with the oncoprotein, Ski, to suppress 
Smad2 transcriptional activity [94]. It may thus be that JNK inhibition is 
coordinated with TGFβ1-activated Smad2/4 binding to the Snail1 gene promoter 
region. Although it is reported that TGFβ1 regulates cross-talk between Smad and 
JNK signaling during EMT of rat peritoneal mesothelial cells [95], there are other 
reports that c- Jun activity is inversely correlated with TGFβ1 and Smad signaling 
activity [96, 97] , in agreement with this study.   Therefore, this study reveals that 
MDA-MB-231 cells embedded in 3D collagen gels and exposed to various 
microenvironmental parameters inactivate the JNK/c-Jun signaling pathway, which 
was in turn coordinated with the TGFβ1/Smad2/4 activation to promote Snail1 
transcription.  This effect was observed only in cells embedded in 3D collagen 
gels, but not in cells cultured in 2D environments, 3D Matrigel, or 3D mixture of 
collagen I and Matrigel, indicating a specific communication existing between the 
１０８ 
3D microenvironment and the cells.  We demonstrated here that Snail1 could 
suppress cortactin expression.  Cortactin is an actin binding protein at actin-
enriched invasive morphological features, such as invadopodia [98].  Snail1 could 
bind to the CTTN promoter and suppressed cortactin mRNA and protein levels 
only when JNK was inactivated in the cells embedded in 3D collagen gel.  In 
addition, cortactin and MT1-MMP invadopodia markers were dynamically 
localized along the cellular boundaries in control cells, but enriched at perinuclear 
regions upon JNK inhibition or Snail1 overexpression. Thus, JNK inhibition 
mediated effects (cortactin suppression and perinuclear localization of cortactin and 
MT1- MMP) decreased invadopodia formation and invasion in 3D collagen gels.  
As suggested in previous studies where Snail1 does not elicit a complete EMT [88] 
and that invasion is not dependent on an EMT phenotype [99], Snail1-decreased 
cell invasion in this study may be relevant to DCIS; noninvasive DCIS may be 
maintained by Snail1-mediated suppression and/or abnormal localization of 
cortactin and/or MT1-MMP, following the JNK/c-Jun pathway inactivation via 






Although an in vitro 3D environment cannot completely mimic the in vivo tumor 
site, embedding tumor cells in a 3D extracellular matrix (ECM) allows for the 
study of cancer cell behaviors and the screening of anti-metastatic reagents with a 
more in vivo-like context. Here I explored the behaviors of MDA-MB-231 breast 
cancer cells embedded in 3D collagen I.  Diverse tumor environmental conditions 
(including cell density, extracellular acidity, or hypoxia as mimics for a continuous 
tumor growth) reduced JNKs, enhanced TGFβ1/Smad signaling activity, induced 
Snail1, and reduced cortactin expression. The reduced JNKs activity blocked 
efficient formation of invadopodia labeled with actin, cortactin, or MT1-MMP. 
JNKs inactivation activated Smad2 and Smad4, which were required for snail1 
expression. Snail1 then repressed cortactin expression, causing reduced 
invadopodia formation and prominent localization of MT1-MMP at perinuclear 
regions. MDA-MB-231 cells thus exhibited less efficient invasion in 3D collagen I 
upon JNKs inhibition. These observations support a signaling network among 
JNKs, Smads, Snail1, and cortactin to regulate the invasion of MDA-MB-231 cells 
embedded in 3D collagen I, and this system may likely be a platform for screening 








Fig. Ⅲ-11. Migration and invasion of MDA-MB-231 cells in 3D collagen gels 


















EMT is a process by which epithelial cells lose their cell polarity and cell-cell or 
cell-matrix adhesion, and subsequently accompanies morphological changes of cell 
and gains migratory and invasive properties to become mesenchymal cells. In this 
study, I investigated how EMT causes gefitinib resistance and how mesenchymal 
properties of cancer cells following EMT process could regulate invasion of 
TM4SF5-positive and E-cadherin negative cells through 3D collagen I gel systems. 
As the results shown in the chapter 1, EMT-mediated gefitinib resistance occurred 
increase in expression of TM4SF5 and TM4SF5-mediated gefitinib resistance was 
involved in EMT. Additionally, in some results showed that EMT-mediated 
TM4SF5 and regulation of activity or integrity of EGFR may likely be important 
for gefitinib resistance of cancer cells. TM4SF5 induced EMT for enhanced cell 
migration and invasion. In the chapter 2, I investigated using the highly-invasive 
and TM4SF5-positive MDA-MB-231 breast cancer cells, their invasive properties 
such as invadopodia formation and ECM degradation in 3D collagen I gels with 
normal serum-containing media were monitored for the underlying mechanisms. 
The results showed that MDA-MB-231 cells by JNKs inhibition caused an 
elongation in cellular morphology and invasion of MDA-MB-231 cells in 3D 
collagen gels were regulated by c-Jun/ TGF-β1/ Snail1/ Cortactin linkage. 
Altogether, this study reveals that mesenchymal properties acquired by EMT 
process, which can be induced by membrane proteins such as TM4SF5 can cause 
drug resistance and enhanced metastatic potentials of cancer cells, suggesting that 






Fig. Ⅳ-1. EMT is correlated with TM4SF5-mediated gefitinib resistance in 
NSCLC cells and invasion of mesenchymal-like cells following EMT process is 
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암세포 부착 기능에 의한 항암제 내성 유발 기전 
및 3 차원적 전이 제어에 관한 연구 
李 美 淑 
 
EGF 수용체 돌연변이가 원인이 되어 발생한 일부 폐암 환자는 
TKI(tyrosine kinase inhibitor)인 gefitinib 과 같은 항암제를 복용하며 
암을 치료한다. 그러나 지속적인 gefitinib 치료는 EGF 수용체에 또 다른 
돌연변이를 유발하거나, c-MET 의 증폭 혹은 EMT (epithelial 
mesenchymal transition)등의 신호 전달경로가 활성화되면서 획득 
저항성(acquired resistance)을 얻게 되어 더 이상 항암제로 작용하지 
못하게 된다. 본 연구는 EGF 수용체의 돌연변이로 인해 발생한 
비소세포 폐암 (non-small cell lung cancer, NSCLC)에서 항암제의 획득 
저항성이 세포 막단백질인 TM4SF5 (Transmembrane 4 L6 family 
member 5)와 상관관계가 있는지, 또 TM4SF5 에 의해 발생하는 
１２４ 
EMT 가 이러한 저항성에 어떻게 영향을 미칠 수 있는지를 살펴보았다. 
그 결과 gefitinib 저항성이 있는 폐암 세포는 TM4SF5 의 발현이 높게 
유지되며, TM4SF5 의 하위 신호로 알려진 세포질의 p27Kip1 을 안정화 
시킴으로써 간엽계(mesenchymal) 세포의 표현형을 나타내는 것을 
확인하였다. 더불어 gefitinib 에 민감한 세포에서도 EGF 수용체에 획득 
돌연변이인 T790M 돌연변이가 추가적으로 생기게 되면 저항성 있는 
세포로 전환되면서 TM4SF5 와 cytosolic p27Kip1 인산화가 높게 
유지되며 세포연접에 중요한 E-cadherin  발현이 감소되어 세포가 
gefitinib 에 저항성을 나타내어 survival 신호를 활성화 시키게 되는 것을 
확인하였다. 부가적으로 gefitinib 에 민감함 세포에 TM4SF5 를 과량발현 
시키게 되면 gefitinib 의 감수성이 떨어졌으며, gefitinib 저항성이 있는 
세포에서 TM4SF5 또는 p27Kip1 을 억제시키면 다시 gefitinib 에대한 
민감성을 회복하게 된다는 사실도 확인하였다. 본 연구 결과는 비소세포 
폐암에서 항암제의 획득 저항성이 TM4SF5 의 발현을 증가시키며, 
이렇게 증가된 TM4SF5 에 의한 EMT 가 gefitinib 의 저항성에도 영향을 
주고 있음을 증명하고 있다. 선행 연구를 통해 우리는 TM4SF5 에 의해 
유도된 EMT 가 항암제의 저항성 뿐만 아니라 암전이에도 중요하게 
영향을 미친다는 것을 알고 있다. 약물에 대해 저항성을 갖게 되는 
암세포는 주변 미세환경 인자와의 소통을 통해 전이를 위한 이동 및 
침윤의 기능을 갖게 된다. 암세포의 약물 저항성과 전이능력은 세포 
미세환경 인자에 의해 영향 받을 수 있을 것이다. 기존의 항암제 개발은 
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암세포를 이차원적 환경에서 단층 배양하여 항암제의 효능을 검증하고 
drug efficacy 를 측정하여 암세포의 침윤과 전이를 연구하여 왔으나 
항암제 개발의 성공 확률을 높이기 위해 삼차원 세포배양 방법을 
도입하여 암세포의 침윤 과정을 모니터링 함으로써 암세포의 이동과 
침윤 억제를 위한 물질 개발에 보다 현실적으로 기여 할 수 있을 것으로 
기대하였다. 이러한 가정하에 강한 전이능을 가진 MDA-MB-231 
세포와 그 외의 유방암 세포를 삼차원 콜라젠 젤 안에 embedding 한 후 
세포의 behaviors 를 연구했다. 우선 암세포의 밀도, 주변의 산성도와 
산소 포화도 등 다양한 세포 미세환경 인자들이 조절될 때 삼차원 
콜라젠 젤 안에서 세포의 증식과 다양한 신호 인자들이 어떻게 변하는지 
살펴보았다. 그 결과 삼차원 콜라젠 젤 안에서의 세포배양은 다양한 
세포 미세환경에 영향을 받아 c-Jun 의 활성을 감소시키고 Cortactin 의 
발현을 감소시켰으며, 전사 인자인 Snail1 의 양을 증가시킨다는 사실을 
확인하였다. 이를 바탕으로 본 연구는 다양한 실험적 방법으로 콜라젠 
젤 안에서 증가된 Snail1 이 Cortactin 의 발현을 감소시켜 결과적으로 
암세포의 침윤에 중요한 invadopodia 의 형성이 억제 되는 것을 
확인하였다. 뿐만 아니라 Cortactin 의 감소는 암세포 침윤 시 세포막에 
위치하여 기질을 분해해 주는 MT1-MMP 의 localization 에도 영향을 
준다는 것을 확인하였다. 본 연구는 삼차원 세포배양을 이용하여 초기 
유방암인 유관상피내암(Ductal Carcinoma In Situ, DCIS)에서 침윤성 
유방암(Invasive Ductal Carcinoma, IDC)으로 전이되는 과정을 유사하게 
１２６ 
보여주는 in vitro 실험 시스템으로 이용될 수 있을 것이며, 암세포의 
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